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This project was concerned with the synthesis of nanoparticles (NPs) by microfluidics from 
bulk ginseng polysaccharides (PS) isolated from American ginseng to design a new 
delivery system to improve the bioavailability of PS. Physicochemical analyses showed 
products of nanosizing as unimodal spheres with a diameter of ~19 nm. Pharmacological 
characterization studies in vitro of these nanoparticles of PS (NPPS) have demonstrated 
heightened immunostimulatory activity, and enhanced penetration across skin cell 
monolayer, which could be considered as evidence of increased bioavailability.  Studies 
using PS sub-fractions with different molecular weights for NPPS synthesis showed that 
molecular weights is one of the parameters that influence the quality of NPPS. Mechanistic 
study revealed that NPPS acted like PS in targeting the Toll-like receptor-signalling 
pathway in mediating the immune-stimulatory effect. This nanotechnology may be applied 
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1.1     Relevance of medicinal plants in modern medicine 
Throughout history, medicinal plants have been used to treat common ailments, alleviate 
discomfort, prevent infection, maintain wellness and restore health1–3.  A medicinal plant 
is defined as a plant which contains one or more bioactive compounds in any part(s) of the 
plant that can be used for therapeutic purposes or as precursors for the development of 
drugs. These bioactive compounds (i.e., phytochemicals) include alkaloids, flavonoids, 
tannins, saponins, phenolics, terpenoids, and carbohydrates, to name a few4. The discovery 
of a plant’s medicinal value was often accidental, through observation or trial and error. 
The development of herbalism relied heavily on oral tradition to pass down centuries of 
knowledge until the advent of writing and record keeping. Herbal knowledge differs 
geographically due to regional ecozones. In some cultures, herbal medicine has developed 
into relatively more advanced systems referred to as traditional medicines. Traditional 
Chinese, Native American, African, and East Indian Ayurvedic medicine are such 
examples.  
 
Within North America, it is estimated that ~70% of Canadians regularly take natural health 
products (NHPs) in the management of their health5. Under the Natural Health Products 
Regulations (Canada), NHPs include: “vitamins and minerals, herbal remedies, 
homeopathic medicines, traditional medicines such as Traditional Chinese Medicines, 
probiotics and other products like amino acids and essential fatty acids”6. These NHPs are 
regulated under the Natural and Non-prescription Health Products Directorate. In Canada, 
a 2011 Functional Foods and Natural Health Products survey reported revenues of $11.3 
billion, with exports of $1.7 billion and $238 million going into research and development7. 
 
It is a common misconception that the entirety of a traditional medicine system is a pseudo-
medicine or placebo-medicine. Although there are such cases, including homeopathy, 
traditional medicine systems contain many medicinal plants which have been identified to 
contain bioactive compound(s)1. The bark of the Pacific Yew is one Native American 
example which has been researched and developed into Taxol - a chemotherapeutic8. 
Traditionally, it was used to treat several complaints ranging from gastrointestinal to 
respiratory ailments. In the 1960s, Taxol was isolated from the Pacific Yew and reported 
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to exhibit anti-tumor properties8. Further research validated its potential as an anti-tumor 
compound and by 1979, it was reported by Schiff et al. that the compound was an anti-
mitotic agent that promotes microtubule stability, thereby inhibiting cell growth by halting 
cell division and ultimately resulting in cell death9. Recently, artemisinin from sweet 
wormwood (Artemisia annua) and its derivatives have been used to treat malaria10. It has 
been traditionally used for dyspepsia, appetite loss and biliary dyskinesia11. Artemisinin 
combination therapy has been estimated to have averted ~146 million clinical cases during 
2000 – 201510. Other well-known examples include acetylsalicylic acid from Salix spp., 
atropine from cocaine from Erythroxylim coca, digitoxin from Digitalis purpurea, 
ephedrine from Ephedra sinica, galanthamine from Leucojum aestivum, morphine from 
Papaver somniferum, quinine from Cinchona ledgeriana, and, vincristrine or vinblastine 
from Catharantus roseus1. 
 
Application of ethnobotany to pharmacology has classically been utilized to bridge 
naturally occurring substances to treat various diseases and conditions12. Medicinal plants 
that have been traditionally used for the treatment of certain illnesses can be screened for 
potential bioactive compounds12. However, some medicinal plants contain multiple 
bioactive components that act synergistically on different targets13. Thus, making it 
difficult to screen for a specific compound. 
 
1.2     Ginseng  
1.2.1     Historical background 
Ginseng is a deciduous perennial herb part of the Araliaceae family within genus Panax 
and is found in Asia (Panax ginseng) and North America (Panax quinquefolius)14. Various 
other species of ginseng have also been identified in around 11 other regions such as Panax 
notoginseng, Panax trifolius or Panax vietnamensis, to name a few14. The genus Panax 
originates from the Greek word “panaxos’ which literally translates into “cure all” or “all-
healing”14. The species ginseng originates from the Chinese characters “rénshēn”, meaning 
“person-herb” since the shape of the root is similar to the shape of a human2. Ginseng-
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derived products are often referred to as adaptogens, which are non-toxic and non-specific 
(i.e., global/ broad effects) substances thought to increase physiological resistance to 
biological stress. The term ‘adaptogen’ was first introduced in the late 1940s; however, 
adaptogenic effects are not well received by the public due to the lack of research behind 
its non-specific benefits.  
 
Ginseng has been historically used in Traditional Chinese Medicine (TCM). In TCM, 
normal body function is described to be controlled by a balance of Yin and Yang, the two 
opposite but complementary forces. Moreover, foods and medicinal plants are classified 
according to their natural properties, such as temperature characteristics (hot, warm, 
neutral, cool and cold); and these properties could impact on the Yin –Yang balance. It is 
believed that unwellness or illness occurs when there is a Yin – Yang imbalance of Yin 
and Yang, and that sickness can be resolved through rebalancing. Historically, Panax 
ginseng (Asian ginseng) is described to have ‘warm’ properties, whereas Panax 
quinquefolius (American ginseng) is described as having ‘cool’ properties.  Prior to its 
introduction and trade to Asia, American ginseng was used in Traditional Native American 
medicine to relieve cold sore, fever, and gastrointestinal distress15. 
1.2.2   Bioactive constituents of ginseng 
Ginseng contains many bioactive compounds include ginsenosides, polysaccharides, 
peptides, triterpenoids, flavonoids, polyacetylenic alcohols, essential oils, fatty acids and 
antioxidants16,17. These compounds are present in all ginseng species with a degree of 
variation18,19. The diverse range of bioactive compounds present in ginseng could explain 
why it has been traditionally utilized to treat or alleviate the symptoms of a broad range of 
illnesses and ailments2,15,19. Recent research has reported that ginseng exhibits 
immunostimulatory, immunosuppressive, anti-mutagenic, anti-tumor, anti-oxidative, and 
hypoglycemic effects20–23. In particular, the pro-inflammatory effects of ginseng have been 
mainly attributed to polysaccharides20. Beneficial effects on halting or slowing the 
progression of atherosclerosis, osteoporosis, arthritis, depression or diabetic complications 




1.3     Plant Polysaccharides 
Plant polysaccharides (PS) are macromolecules made up of long chains of 
monosaccharides linked together by glycosidic bonds (Fig 1.1)29. In general, plant cells 
contain mainly starches, pectins, cellulose and hemicellulose. Starches are glucans 
composed of α-(1,4)-glycosidic linkages (i.e., amylose) and may contain α-(1,6)-glycosidic 
linked branches along the main chain (i.e., amylopectin)30. These PS are found in the 
amyloplasts of plant cells and are the main glucose storage component of plants. Pectins 
are also composed of α-(1,4)-glycosidic bonds and maybe branched30. Pectic 
polysaccharides are high in galacturonans and may exist as homopolysaccharides or 
heteropolysaccharides30. They are found in the middle lamella and within the plant cell 
wall, and function as a structural component. Cellulose is composed of unbranched glucans 
with β-(1,4)-glycosidic bonds30. In contrast, hemicellulose is branched 
heteropolysaccharides composed of α- and β-glycosidic linkages31. Cellulose and 
hemicellulose are located in the plant cell wall and function as a structural component. 
 
Polysaccharides are recognized as biological polymers due to the high degree of variation 
in the number and type of repeating monomers, conformation, functional groups and 
degree of branching. PS are heterogeneous with wide molecular weight distribution 
because of the broad differences in structure between individual PS30. The differences in 
structure also lead to variation in solublity30. Aside from the type of glycosidic bonds 
present in PS, the main repeating monosaccharide unit(s) determines the subtype of PS 
(e.g., pectin: type II rhamnogalacturonan).  In general, plant PS are hydrophilic due to the 
presence of multiple hydroxyl groups30. However, they become more hydrophobic with an 
increasing number of internal hydrogen bonds30. PS with more intramolecular hydrogen 
bonding interact less with water decreasing its hydration30.  
1.3.1 Chemical structure of ginseng polysaccharides 
Plant PS isolated from ginseng are structural and soluble PS that originate from the plant 
cell walls. They mainly consist of starch-like PS, pectin PS and hemicellulose31. As 
aforementioned, the structure of the PS differs greatly between individual PS. Starch-like 
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PS mainly contains branched α-(1,6)-glucans, α-(1,2)-glucans and α-(1,3)-glucans32. Pectic 
PS are primarily rich in homogalacturonans with a molar ratio of up to 70% and a small 
degree of branching33. They are composed of rhamnose (Rha), arabinose (Araf), galactose 
(Gal), glucose (Glc) and uronic acid (A) (1:4:8:8:50)33. A minority of ginseng pectic PS 
has been identified as type 1 rhamnogalacturonans33. Guo et al. demonstrated that these 
pectic PS exhibit similarity to several citrus pectins33. The main sugar residue of these 
pectins is 4-α-D-GalA and other residues like 2-α-L-Rha, 2-4-α-L-Rha, α-L-Araf, β-D-Gal 
and 4-β-D-Gal33. Recently, ginseng hemicellulose has been shown to predominantly 
consist of β-glycosylic-linked xylans, xyloglucans and glucomannans31. In addition to the 
different types of ginseng PS, individual PS may have a different number of monomeric 
repeats. The diversity and complexity of PS result in the heterogeneity of ginseng PS.  In 
particular, the molecular weight of ginseng PS can range from as low as 3.1 kDa to as high 
as 2,000 kDa34,35.  
 
Ginseng PS are also broadly separated into two categories: acidic and neutral PS31. Acidic 
PS contains Gal, Rha, Ara, Glc and mannose (Man) that are high in GalA and GlcA31,36. 
These acidic PS are generally pectins30. Neutral PS includes starch-like glucans that are 














1.3.2 Chromatography, detection and quantitative analysis of PS 
The analysis of plant polysaccharides is a challenge due to low UV/Vis 
(Ultraviolet/Visible) absorbance and high complexity. As such, quantitation based on 
UV/Vis absorbance such as High Performance Liquid Chromatography (HPLC) using a 
UV/Vis detector is unsuitable37. HPLC using a Refractive Index (RI) detector is also 
unsuitable to analyze PS due to problems with sensitivity37. HPLC-RI is often performed 
on homogenous solutions; however, PS are highly complex and heterogeneous which 
would result in a broad range of RI values. Baseline stability is also a concern when using 
HPLC-RI for PS because any changes to the eluent composition would require re-
equilibration of the detector. Evaporative Light Scattering Detector (ELSD) has been 
previously used to analyze PS composition because it can detect compounds which are less 
volatile than the mobile phase rather than detecting optical properties37. Despite the 
benefits of this analytical technique, the quantification of PS concentration is still a 
problem. Plant PS lack chromophoric moieties, therefore, labelling PS with a fluorescent 
tag would allow for the detection of PS molecules38. Concentration can be quantified with 
the use of a fluorometer, but this technique is limited by the selectivity of labelling, which 
has yet to be addressed. Alternatively, it is possible to quantify plant PS by conducting a 
biological assay and calculating concentration from a preconstructed standard curve. A 
sensitive assay, such as Griess’ assay to detect nitric oxide (NO) or enzyme-linked 
immunosorbent assay (ELISA) to detect interleukin (IL)-6 or tumor necrosis factor alpha 
(TNFα) could be used to build this standard curve. 
1.3.3   Extraction and isolation of plant polysaccharides    
Ginseng PS are typically extracted and isolated from the plant biomass through hot-water 
extraction followed by precipitation of PS with alcohol. The precipitate can be further 
purified to yield deproteinated PS (i.e., bulk PS). Briefly, a methodology to extract PS from 
North American ginseng roots was developed by Professor Lui and Charpentier’s group at 
Western University, Canada. First, ground-up ginseng roots were soaked in water at 40 °C 
for 5 hours to yield a water-soluble extract. The extract was then concentrated to remove 
excess solvent and lyophilized to obtain a dry aqueous extract. To isolate PS, the dried 
aqueous extract was dissolved in distilled water at a known concentration and four 
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equivalent volumes of 95% ethanol were added to the aqueous solution and lyophilized to 
obtain the powdered PS extract. The water-soluble PS extract was be furthered processed 
to remove proteins and yield the deproteinated water-soluble PS extract.  
1.3.4 Immunomodulatory and antioxidant effects of plant polysaccharides 
The effects of PS vary depending on their origin and composition. Generally, plant PS are 
immunostimulatory and act primarily on macrophages and circulating monocytes. Other 
effects including immunosuppressive, antimicrobial and antioxidant activities have also 
been reported20,39. Various plant PS have been recently demonstrated to elicit these effects 
in vitro and in vivo. For example, PS isolated from Sargassum fusiforme, a brown sea 
vegetable, have been reported to stimulate peritoneal macrophages through toll-like-
receptor (TLR) 2 or TLR4 pathway via P38 mitogen-activated protein kinases (MAPK)40. 
The proliferation of splenic lymphocytes and immunoglobulin M (IgM) expression were 
both enhanced in cells treated with these PS. In another study, Sargassum fusiform PS 
stimulated TNFα, IL-1 and IL-6 production in RAW 264.7 (Abelson mouse leukemia virus 
transformed) macrophages41. This was mediated by NF-κB signalling via the cluster of 
differentiation 14 (CD14)/ inhibitor of nuclear factor kappa-B kinase (IKK) and p38 
MAPK pathway41. Similarly, PS isolated from a heart-leaved moonseed, Tinospora 
cordifolia, have been shown to upregulate TNFα, IL-1β, IL-6, IL-12 and interferon-gamma 
(IFNγ) in RAW 264.7 macrophages and peritoneal macrophages42. Non-starch PS high in 
galacturonic acid has also been shown to increase NO, TNF-α and IL-6 production in 
macrophages (RAW 264.7) through the TLR4 pathway43. These non-starch PS were 
isolated from Dioscorea polystachya (Chinese Yam). PS isolated from fungi such as 
Grifola frondosa (Hen-of-the-wood) have demonstrated similar effects44. Murine 
macrophages (RAW 264.7) treated with these PS-induced morphological changes, 
increased IL-1β, IL-10 and NO production44. 
 
Ma et al. recently reported dose-dependent antioxidant effects exhibited by red onion 
(Allium cepa) PS that were sequentially extracted using hot buffer, chelating agent, dilute 
alkali and concentrated alkali39. The authors demonstrated that the degree of radical 
scavenging, iron chelating, lipid peroxidation inhibition and reducing power was 
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influenced by the PS composition39. The monosaccharide composition of these four PS 
fractions was previously shown to be different from each other45.  Using the same 
extraction methodology, PS extracted from mulberry leaves (Morus alba) also exhibited 
dose-dependent antioxidant effects. Likewise, the degree of antioxidant activity was 
dependent on monosaccharide composition46. Interestingly, the antioxidant activity of 
plant PS can be enhanced through hydroxyl modifications. Li et al. showed the antioxidant 
activity of PS extracted from peony seed dreg (sediments) can be positively altered by 
sulfation, phosphorylation or carboxyl methylation47. 
 
1.3.4.1   Biological effects of ginseng polysaccharides. 
Ginseng PS exhibit a broad range of biological effects and have been widely reported for 
their immunomodulatory and antioxidant properties. In a study investigating the 
immunomodulatory effects of ginseng PS in murine peritoneal macrophages, PS isolated 
from a ginseng extraction by-product enhanced hydrogen peroxide (H2O2) and NO 
production48.  Lim et al. reported that PS-treated macrophages had stimulated lysosomal 
phosphatase and phagocytic activities48. Sun et al. recently found enhanced natural killer 
(NK) cell cytotoxicity in PS-treated immunosuppressed mice, specifically via the 
upregulation of perforin and granzyme49. Similarly, Azike et al. reported that PS treatments 
exerted immunostimulatory effects on macrophages20. IL-6, TNFα and NO were 
upregulated in a dose-dependent manner20. The authors also showed that pre-treating 
murine macrophages with PS-induced attenuation of immune response20. Azike et al. also 
found that the potency of PS was positively correlated to its molecular weight range50. 
 
The immunostimulatory activity of the PS is also related to their type, such as acidic or 
neutral PS. It was previously shown that the bioactive species of PS were mainly acidic 
and not neutral PS37. In one study, rat alveolar macrophages did not respond significantly 
to treatment with neutral PS but responded to acidic PS37. Pretreatment of macrophages 
with neutral PS resulted in minimal immunosuppressive effects in LPS-stimulated 
macrophages37. In a recent study, a novel neutral PS (3.1 kDa) isolated from North 
American ginseng and was reported to have significant anti-inflammatory activity35. Yu et 
al. demonstrated that acidic PS were more immunostimulatory compared to neutral PS51. 
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In addition, neutral PS were found to be less immunostimulatory than crude PS isolate51. 
Shin et al. showed that acidic ginseng PS stimulated immune cells and upregulated the 
production of TNFα, IL-6, IL-1β and IFNγ52. Similarly, Park et al. investigated the 
immunomodulatory effects of acidic PS extracted from Panax ginseng53. Their study 
revealed that acidic PS-treated mice had higher levels of inducible nitric oxide synthase 
(iNOS) production compared to the control mice53.  Moreover, the addition of an iNOS 
inhibitor (i.e., aminoguanidine) along with acidic PS attenuated the PS-mediated- immune 
suppression in sheep red blood cells53. The authors also showed that macrophages treated 
with acidic PS have increased cytotoxic activity53. In particular, elevated NO and H2O2 
production and increased phagocytic activity were measured53.  
 
Pectin-like PS exhibited similar immunostimulatory effects as glucans. For example, 
increased proliferation of splenocytes and activation of peritoneal exudate macrophages 
and NK cells were reported in pectin-treated mice54. Recently, a novel pectin-like PS 
extracted in the presence of ethylenediaminetetraacetic acid (EDTA) was demonstrated to 
stimulate T and B lymphocyte proliferation55. 
 
1.3.4.2   Ginseng-polysaccharides-derived natural health products.  
Several products containing ginseng PS have been marketed and approved by Health 
Canada; however, many do not have substantial research on their efficacy and safety for 
consumption. Of note, CVT-E002 (i.e., COLD-FX®) claims to help reduce the frequency, 
severity and duration of cold and flu symptoms by boosting the immune system56. CVT-
E002 is a North American Ginseng PS extract which has been demonstrated to reduce 
eosinophilic airway inflammation in asthma-induced mice57. Adamko et al. also found that 
CVT-E002 reduced airway reactivity57. Moreover, CVT-E002 stimulated proliferation of 
murine B lymphocytes and production of NO, TNFα, IL-1 and IL-6 in peritoneal exudate 
macrophages58. In addition, an elevation in immunoglobulin G (IgG) production was 
observed in mice treated with CVT-E00258. These results have been recently replicated by 
Song et al. who reported that immunosuppressed mice treated with CVT-E002 increased T 
and B lymphocyte proliferation and, NK cell activity59. Another recent publication reported 
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that CVT-E002 stimulated the proliferation of T and B cells and production of IL-10 and 
IL-6 in mice60. 
 
1.4     Innate immunity  
The non-specific immune response of the host to foreign substances (i.e., antigens) and 
microorganisms such as viruses, bacteria, protozoa and fungi are the initial line of defense 
against infection. The first aspect of innate immunity is physical and chemical barriers 
(e.g., epidermis, intestinal epithelium, saliva, bile, stomach acid, etc.) which prevent or 
limit exposure to foreign materials and cells. Cellular and molecular components present 
in the tissues and circulatory system such as dendritic cells, NK cells, mast cells and 
phagocytes, as well as complements or inflammatory mediators are another aspect of innate 
immunity61,62. The former is involved in the capture and elimination of pathogens, 
particles, cellular debris or infected cells61. Complements and inflammatory mediators are 
responsible for the enhancement of phagocytic activity via opsonization and the 
recruitment and activation of phagocytes, respectively62. Other components of the innate 
immune system include neutrophils, granulocytes (basophils and eosinophils), and 
cytokines. Granulocytes produce bactericidal proteins, reactive oxygen species, histamine, 
as well as cytokines that help regulate cells involved in the innate immune response. A 
crucial function of the innate immune system involves downstream activation of adaptive 
immunity61,63. The adaptive or acquired immune response involves the activation of T and 
B lymphocytes via antigen presentation by innate immune cells and the production of 
memory cells and antibodies targeting specific antigens63. 
1.4.1   Immunomodulation 
Immunomodulation refers to the regulation of the immune system by exogenous or 
endogenous compounds including those that originate from biological stress. 
Immunomodulatory compounds (i.e., immunomodulators or biological response 
modifiers) might act to elicit proinflammatory or anti-inflammatory responses through the 
innate immune system. Some compounds, such as plant PS, can both stimulate and inhibit 
various immune responses35,58. In general, plant PS are known to stimulate immune cells 
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via TLR signalling40,43. Such compounds that can stimulate specific aspects of innate 
immunity are known as immune-stimulants. On the other hand, compounds capable of 
inhibiting specific aspects of the host immune response are referred to as immuno-
inhibitors. Immuno-suppressors are compounds that can attenuate host immune response 
which may occur through a variety of pathways, such as receptor desensitization or via 
inhibition of responses64,65. The goal of desensitization is the attenuation of subsequent 
innate immune responses. For example, desensitization of TLRs in macrophages following 
stimulation by a TLR agonist leads to the reduced presence of cell-surface TLRs. This 
attenuates immunostimulatory responsiveness to subsequent treatment with TLR agonists.  
 
1.4.2    Macrophage-mediated innate immunity    
Macrophages are mononuclear phagocytic leukocytes that are present in tissues and in the 
circulatory system. Those in the blood are referred to as monocytes and are differentiated 
from tissue macrophages. Overall, the functions of macrophages include both the direct 
phagocytosis of foreign material or cellular debris as well as the indirect secretion of 
inflammatory mediators such as TNFα and IL-666. Macrophages also play a role in 
presenting antigens to helper T-cells and are essential in promoting wound closure and 
tissue repair63,66. Macrophages within different tissues exhibit varying morphologies and 
functions which are niche-specific and tissue-specific. For instance, skin-resident 
macrophages (i.e. Langerhans cells) are very heterogeneous in morphology and are widely 
distributed throughout the tissue to act as first responders to potential pathogen invasions67. 
Other examples of tissue-specific macrophages are Kupffer cells in the liver, microglia in 
the central nervous system, dust cells in the lung, osteoclasts in the bone, sinus histiocytes 
in the lymph nodes and adipose tissue macrophages in body fat. 
 
It was long-believed that macrophages were classically activated by cytokines IFNγ and 
TNFα produced by helper T-cells or alternatively activated by regulatory T cell-released 
IL-1066. While it remains true that macrophages polarize toward one phenotype in response 
to specific signals and are associated with different functions, research in the past decade 
has led to a paradigm shift in our understanding of the activation of macrophages and the 
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requirement of T-cells. In light of this, macrophages are classified into two general groups, 
M1 and M2 macrophages, based on their response or activation/polarization by specific 
stimuli66,68,69. The two groups represent two sides on a linear scale. M1 macrophages lean 
towards the ‘inhibit’ or ‘kill’ function, whereas M2 macrophages lean towards the ‘healing’ 
or ‘repair’ function69,70. M1 macrophages that were previously known as the classically 
activated macrophages are activated by pathogen associated molecular patterns (PAMPs), 
damage-associated molecular patterns (DAMPs), TNFα or IFNγ70,71. These macrophages 
are mainly pro-inflammatory and phagocytic which produce high levels of IL-12 and low 
levels of IL-1068. On the other hand, M2 macrophages, previously known as alternatively 
activated macrophages, are activated by inflammatory mediators such as glucocorticoids, 
IL-4, IL-10, IL-13 or prostaglandins66,72,73. Collectively, these stimuli are referred to as M2 
stimuli and the response is mainly anti-inflammatory. M2 is further sub-grouped into M2a, 
M2b, M2c and M2d depending on the stimuli or response. In general, M2 macrophages are 
involved in wound healing, allergy regulation and Th2 responses, and produce higher 
levels of IL-10 compared to M1 macrophages68,69,74. In addition, M2 macrophages are 
thought to be the basal phenotype of tissue-resident macrophages70. They are not activated 
into M2 macrophages, but rather present as M2-like or M2-deactivated macrophages under 
basal conditions. Alternatively, these macrophages are referred to as unprimed or naïve 
macrophages (M0)
75. In the absence of external physical stress, resident macrophages 
remove cellular debris and senescent cells. Resident macrophages can quickly develop into 
the M1 phenotype or stay as M2 depending on the stimuli; however, the response of 
resident macrophages is tissue-specific and niche-specific69,70. During wound-healing, the 
less inflammatory M2 macrophages are the predominant phenotype, and M2-type 
responses are modulated69,70. They promote tissue formation and inflammation resolution 
through the release of growth factors and phagocytosis of apoptotic neutrophils69,76. 
 
Macrophage cell lines such as RAW 264.7 or bone-marrow derived macrophages (BMDM) 
are naïve or unprimed (i.e., M0) macrophages and can be polarized to M1 or M2 
phenotype75. RAW 264.7 cell line – which was used in this study – are 
monocyte/macrophage-like cells established from ascites of a tumor induced by Abselon 
Leukaemia Virus in BALB/c mice. They have been described as an appropriate model of 
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macrophages and can be polarized to M1 or M2 via IFNγ or IL-4, respectively77,78. In 
addition, RAW 264.7 cells can be differentiated into osteoclasts with RANKL (receptor 
activated NF-kappa B ligand)79. Compared to other cell lines, RAW 264.7 cells are 
morphologically unique (elongated; projections). Although its phenotypic and functional 
stability was initially described by ATCC to lose stability after passage 18, a recent paper 
recommends the use of up to passage 3077. 
 
1.4.3   Lipopolysaccharides (LPS) 
M1 macrophages are activated in response to PAMPs which are derived from bacteria and 
other foreign microorganisms68,70. PAMPs are recognized by pattern recognition receptors 
(PRR) on the macrophages70. Endotoxin or bacterial lipopolysaccharide (LPS) is a well-
reported PAMP originating from the outer monolayer of the outer membrane of gram-
negative bacteria80. LPS binds to cell-surface TLRs which are a class of pattern recognition 
receptors (PRRs) found in phagocytes such as neutrophils, macrophages and dendritic 
cells80. LPS are made up of a lipid A and polysaccharide portion80. The polysaccharide 
portion has three regions: O-antigen, outer core and inner core80. Lipid A is a glucosamine-
based phospholipid and its main function is to enhance the outer membrane stability80. The 
toxicity level of LPS is mainly attributed to its lipid A region. The O-antigen region is not 
essential for TLR4 binding; however, LPS that lack an O-antigen region (i.e., rough LPS) 
does not require the help of lipid binding protein (LBP) and CD1481,82. Both forms of LPS 
are highly toxic and can elicit a response from macrophages and monocytes even at a 
concentration as low as 10 – 500 pg/mL for LPS83. Overall, excessive TLR signalling by 
LPS binding results in fever, hypotension and eventually septic shock that leads to 
widespread organ failure.  
 
The binding of LPS to TLRs is enhanced by LBP, a soluble protein. LBP non-covalently 
binds LPS and delivers LPS to cluster of differentiation 14 (CD14) or TLRs82. The 
interaction of LBP and CD14 with LPS forms a ternary complex82. The ternary complex 
facilitates the transfer of monomeric LPS to TLR4/myeloid differentiation factor-2 (MD-
2) complex82. MD-2 is co-expressed with TLR4, which is vital for the TLR4 response to 
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LPS as well as the recognition of lipoteichoic acid from gram-positive bacteria84. Aside 
from presenting LPS to the TLR4 complex, CD14 mediates translocation of the TLR4 
complex to an endosome85. Therefore, CD14 is essential for early and late phase (i.e., 
endosomal) TLR4-signalling.  
 
1.4.3.1 Toll-like receptor (TLR) 4 signaling 
TLR4 signalling is activated upon ligand recognition by the leucine-rich repeat domain 
(LRR) of the TLR4 and dimerization of the TLR4/MD-2/ligand complex via the LRR 
domain86. Dimerization of the TLR4/MD-2/ligand complex enables dimerization of the 
intracellular toll-interleukin 1 receptor (TIR)-domain of TLR486. Subsequently, 
intracellular TLR4 adaptor proteins, which contain TIR-domains, are recruited to the TIR-
domain of TLR487. These adaptor proteins include TIR-domain-containing adaptor protein 
(TIRAP), TRIF (TIR-domain-containing adaptor-inducing interferon-β), TRAM (TRIF-
related adaptor molecule) and MyD88 (myeloid differentiation primary response 88). 
There are two pathways in TLR4 signalling: MyD88-dependent and TRIF-dependent 
pathway.  
 
1.4.3.2 MyD88-dependent signalling.  
In the MyD88-dependent signalling, TIRAP is recruited to TLR4 and binds to the TIR 
domain of TLR4 through its TIR domain88. Upon recruitment, TIRAP facilitates MyD88 
recruitment to TLR4 via indirect binding (i.e., bridging)88. Recruitment of MyD88 results 
in downstream activation of TNF receptor-associated factor 6 (TRAF6) via IL-1R-
associated kinase (IRAK)1/289. This leads to the downstream activation of IKK complex, 
which in turn phosphorylates inhibitor of kappa B (IκBα) and targets it for degradation90. 
Subsequently, NF-κB (nuclear factor-kappa-light-chain-enhancer of activated B cells) 
translocates to the nucleus and binds to promoters target genes including iNOS/NOS2, 
Cyclooxygenase-2 (PTGS2/COX-2), TNFα and IL-6, to name a few91,92. COX-2 and iNOS 




1.4.3.3 TRIF-dependent signalling. 
Following LPS binding, TLR4 complex is internalized into an endosome in a dynamin-
dependent-manner65. The translocation of TLR4 to endosomes is a prerequisite for TRIF-
dependent signalling93. The internalization of the TLR4 complex prevents subsequent 
activation of the MyD88-dependent pathway by TLR4 agonists94. TRIF-dependent 
signalling begins with the recruitment of TRAM to the TIR-domain of TLR495. Similar to 
TIRAP and MyD88, TRAM recruits and bridges TRIF to TLR4 at the TIR-domain95. 
Following association, TRIF binds to TRAF6 which in turn downstream activates NF-κB 
resulting in late-phase NF-κB pathway93,95.  
 
1.4.4 Ginseng PS-mediated activation of TLR signalling 
Ginseng exhibits both immunostimulatory and anti-inflammatory effects. The opposing 
immunological effects have been attributed to the constituent PS and ginsenosides, 
respectively20. However, ginseng PS has also been reported to have anti-inflammatory and 
immunosuppressive effects35,96. Ginseng PS upregulated NO, IL-1β, IL-6, IFN-γ, and 
TNFα production in macrophages through TLR4 signalling52. Studies revealed that ginseng 
PS modulate immune response through NF-κB, p38 MAPK, MAPK1/3 and PI3K 
(phosphatidylinositol 3-kinase) cascades97. In addition, the expression of CD14 proteins in 
macrophages was increased after treatment with acidic PS from Asian ginseng52. LPS has 
been known to act through TLR4 signalling and it was reported that macrophages 
stimulated with LPS exhibited enhanced CD14 expression98. Thus, the upregulation of 
CD14 expression by acidic PS may suggest its involvement in the activation of TLR 
signalling by PS. Moreover, the production of TNFα, IL-1β, IL-6, IFNγ were impaired in 
TLR4 deficient mice (C2H/HeJ) treated with ginseng radix extract99. 
 
Ginseng PS exhibited immunosuppressive effects in LPS-induced models100. McElhaney 
et al. reported that CVT-E002TM suppressed activation of neutrophils and production of 
inflammatory cytokines (i.e., IL-2, IFNγ) in spleen cells induced by LPS stimulation100. 
Similarly, Zhao et al. reported that ginseng PS reduced the expression of TNFα and IFNγ 
in intraepithelial lymphocytes and lamina propria lymphocytes in collagen-induced 
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arthritis rats101. Acidic PS isolated from Asian ginseng exhibited suppressive effects in a 
model of demyelinating disease, experimental autoimmune encephalomyelitis102. The 
extract inhibited autoreactive T-cell proliferation and proinflammatory cytokine (i.e., 
IFNγ, IL1β and IL-17) production, thereby reducing the progression of autoimmune 
encephalomyelitis102. Furthermore, the extract activated FoxP3 transcription factor which 
is a regulator of regulatory T-cells102.  
 
The immunosuppressive or protective effects observed with ginseng PS are likely due to 
endotoxin-tolerance and negative regulation of downstream pro-inflammatory 
responses96,103. Internalization of TLR4 is characteristic of endotoxin-tolerant immune 
cells94,98. The translocation of TLR4 into endosomes has been reported to be regulated by 
CD14 mediated by immunoreceptor tyrosine-based activation motif (ITAM)85. Subsequent 
stimulation of endotoxin-tolerant immune cells with PAMPs (e.g., LPS) may result in a 
reduced immunostimulatory response. Compared to LPS, ginseng PS are non-toxic, lacks 
the lipid A moiety and is markedly less potent29,50. Therefore, the activation of TLR4 
signalling by ginseng PS via CD14 is likely to result in the internalization of TLR4 
mediated by ITAM52,85. This might explain one aspect of the protective effects of ginseng 
PS found in the literature. 
1.5     Nanomaterials 
Nanoparticles are defined as particles with at least one dimension less than 1000 nm but 
greater than 1 nm in diameter; however, they are commonly less than 100 nm. They exhibit 
different physicochemical properties than the substrate (i.e., bulk material) used to 
synthesize them such as solubility, permeability or particle size. In particular, the decrease 
in particle size from its corresponding bulk compound has been shown to enhance its 
uptake by cells (e.g., epithelial cells within the gastrointestinal tract)104. The application of 
nanotechnology to pharmacological agents has provided many benefits, removed various 
pre-existing inconveniences or minimized side-effects; however, the toxicity of 
nanomaterials remains highly controversial. This is because the fate of nanoparticles differs 





There are many characteristics of nanoparticles that are desirable in pharmaceutical 
compounds such as smaller particle size, improved solubility and dissolution or different 
release characteristics (e.g., pH), to name a few104,107–109. Moreover, substrate toxicity can 
be mitigated by encapsulation or surface modifications106,110. In general, the larger surface-
area-to-volume ratio promotes greater molecular interactions and ultimately greater 
cellular uptake111. Change in surface chemistry and enhancement of drug solubility can 
also increase the drug bioavailability109,112,113. Common examples include enhancing the 
lipophilicity of a drug or encapsulating a drug to protect it from degradation and 
metabolism prior to reaching its site of action. Targeted drug delivery via surface 
functionalization is another approach used to address some of the predominant issues in 
the field114. For example, albumin can reversibly bind to a drug (e.g., Paclitaxel) to 
facilitate its transport across the endothelium via glycoprotein 60-mediated transcytosis115. 
Drugs could also be modified with marker-attached polymers (e.g., conjugated antibodies) 
to target its delivery to specific organs/tissues116. The nanoparticle itself can also function 
as a therapeutic agent (e.g., nanocrystals, PS NPs) with enhanced transport and reduced 
crystalline/hydrodynamic size38,104. 
1.5.1 Nanomedicine for topical administration 
The majority of nanotechnology applications to drugs have been directed to orally 
administered drugs with low bioavailability or widespread toxic side effects. Thus far, 
relatively few compounds have been synthesized into nanoparticles for topically 
administered compounds. Many of these are skin care products such as pain relief, 
antiseptics, first-aid compounds, scar treatments, acne creams, anti-aging treatments and 
hydration products.  For example, nanoparticles of zinc oxide (ZnO) and titanium dioxide 
(TiO2) offer a broader range of UV protection than their microparticle counterparts
117,118. 
For physical agents like sunscreens, nanoparticles offer greater transparency as opacity is 
aesthetically unappealing. Nanotechnology has also been applied in the design of skin 




1.5.2 Epidermal drug transport  
Most topically administered drugs require penetration into or across the epidermal layer to 
elicit their pharmacological effect. Thus, the epidermis is present as a physical barrier to 
these drugs. The epidermis consists of keratinocytes that are differentiated and organized 
into the stratum corneum at the superficial layer, followed by the stratum granulosum, 
stratum spinosum and stratum basale. The stratum corneum functions as the main barrier 
against physical trauma, chemical and pathogenic attack, as well as ultraviolet (UV) 
irradiation. In addition, a non-polar lipid barrier formed by lamellar bodies in keratinocytes 
is present at the level of the stratum granulosum67. In the stratum spinosum, keratinocytes 
are connected together by a large number of desmosomes67. Macrophages (i.e., Langerhans 
cells) are also resident to the stratum spinosum67. The stratum basale consists of both 
quiescent and actively proliferating basal keratinocytes that form a monolayer where 
individual cells are connected through tight junctions and are attached to the basement 
membrane67,120. 
 
Transport of drugs across the skin can occur via the paracellular or transcellular, or trans-
appendageal pathway. The polarity and size of molecules are important for bypassing the 
lipid matrix or plasma membrane of keratinocytes and ultimately affects its route of 
transport121. The transport across other cell barriers such as the intestinal epithelium may 
occur by paracellular or transcellular pathways. For skin, paracellular transport involves 
movement through the lipid matrix in intercellular spaces of keratinocytes. Sufficiently 
small particles (< 500 Da) can also be transported paracellularly across tight junctions of 
keratinocytes120,121. Particles which typically undergo this passive process are 
hydrophilic122. In general, particulates that are < 500 nm are transported transcellularly 
through clathrin-mediated, caveolae-mediated or non-specific endocytosis whereas large 
particulates are phagocytosed123. In addition, molecules with a large surface area to volume 
ratio have higher uptake into cells due to greater interaction with membrane receptors124,125.  
1.5.3 Synthesis of nanoparticles 
In general, there are two approaches to synthesizing nanomaterials: top-down (i.e. bulk 
material/ substrate to nanoparticles) and bottom-up (i.e. nanomaterial from atomic or 
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molecular species through chemical reactions)104,126. There are various methodologies to 
synthesize nanomaterials such as nanoprecipitation, microemulsion, nanocrystallization, 
nano-lithography, and milling with their own associated advantages and disadvantages. 
There are also more specialized derivatives of the aforementioned approaches. For 
example, variations of nanoprecipitation include open-microfluidics, continuous-flow 
microfluidics and digital microfluidics38,127,128. 
 
The microfluidic methodology involves using a solvent to first dissolve the bulk 
material/compound, after which an anti-solvent would be added to the dissolved solution 
to decrease the drug solubility and ultimately induce substrate precipitation. The benefits 
of using nanoprecipitation include high efficiency and low-costs. Nanoprecipitation does 
not require high temperatures, ultrasonication, chemical reactions, additional surfactants or 
toxic solvents which can affect the chemical structure of the substrate. The characteristics 
of the nanoparticle can also be controlled by altering the substrate concentration, solvent 
type, ratio of solvents, polymer type and temperature129. One nanoprecipitation method 
involves using water as the solvent and acetone as the anti-solvent. The interaction between 
acetone and water in contact with the substrate precipitates the substrate polymer. The 
precipitate exhibits change in hydrodynamic volume and surface chemistry38. Lamer et al. 
proposed that the formation of the nanoparticle occurs through two steps130. First, 
nucleation of small aggregates of polymer in a supersaturated solution corresponds to a 
reduction in drug solubility by the addition of an anti-solvent. In the second step, the 
nanoparticle nuclei grow until the stability of the colloidal particle has been reached. 
Stabilizers can also be added to prevent the dissolution of particles and redeposition into 
larger particles. The preferential shape of these nanoparticles is spherical because the 
polymer chains are homogeneously distributed in the solution during nanoprecipition131,132.  
 
As mentioned before, microfluidics is a variation of nanoprecipitation. The benefits of this 
technique variant are that the flow rate and/or ratio of the solvent and anti-solvent can be 
controlled. In continuous-flow microfluidics, the solvents are manipulated through 
microfabricated channels connected at a junction. There are two types of microchannel 
geometry: T-junction and cross-junction or flow focusing channels (Fig. 1.2). The 
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interaction between the solvents at the junction promotes the formation of monodispersed 
nanoparticles133. Nanoparticles synthesized by this method are more uniform in size and 








Figure 1.2. Droplet formation using different microfluidic junction geometry (a) cross-
junction and (b) T-junction. 
 
1.6   Summary and Rationale 
Polysaccharides such as pectins and starch-like glucans are key bioactive phytochemicals 
in North American ginseng root. It was recently previously reported that the 
immunostimulatory properties of North American ginseng are chiefly due to this PS 
component. Contemporary studies have also demonstrated that these PS have antioxidant, 
immunomodulatory and immuno-protective properties29,59,134. The potency of ginseng PS 
was shown to be related to its molecular weight – higher molecular weight PS were more 
potent50,97. Evidence indicates that PS elicits an immune response through TLR signalling 
via the NF-kb pathway52. Specifically, TLR4 and CD14 have been implicated in the 
activation of macrophages by ginseng PS52,99. Although ginseng PS are pharmacologically 
active, the effects are limited by its large molecular size which inhibits its absorption in the 
gastrointestinal tract. The bioavailability of PS is also limited by its hydrophilic nature. 
However, the transport of PS has not been comprehensively studied because of the lack of 
chromophores in ginseng PS. Moreover, the limited UV activity of PS poses a challenge 




Application of nanotechnology to ginseng PS to control and modify molecular size 
potentially allows for greater bioavailability. Akhter et al. demonstrated that nanosizing 
ginseng PS by nanoprecipitation using microfluidics reduces the particle size of PS while 
increasing its crystallinity38. These nanoparticles exhibits marked accumulation in the 
dermis, increased cellular uptake and enhanced immunostimulatory activity compared to 
its bulk form38. Their results suggest that these observations are likely to be primarily 
attributed to the physicochemical changes rather than changes to the chemical structure 
following microfluidic processing of the bulk PS38. Various factors may have also 
contributed to the observation of enhanced biological effect such as potential selectivity of 
PS molecules by the microfluidic procedure, change in PS mechanism of action or 
alteration of PS binding kinetics to TLR or CD14. Thus, the basis for the apparent increase 
in PS biological effect and the transport of PS and its nanoparticle needs to be elucidated. 
This study focuses on the characterization of NPPS physicochemical properties and 
investigates if NPPS acts similar to bulk PS. The size and morphology of NPPS and the 
influence of PS molecular weight on the nanomorphology are studied. Furthermore, the 
penetration of NPPS across a monolayer is investigated using a novel bioassay to 
characterize the enhancement of PS transport across a monolayer model. The 
immunostimulatory activity and mechanism of activation of NPPS are studied to determine 
the effects of nanosizing on the pharmacodynamics of bulk PS. 
 






1. Nanosizing ginseng PS using microfluidic processing reduces their particle size and 
improves their permeability across the membrane barrier.  
2. Nanosizing selectively incorporates higher molecular weight and more bioactive 
polysaccharides into nanoparticles rendering higher immunostimulatory activity.  
3. NPPS possess different cellular mechanism of action as compared to bulk PS, and this 




Aim 1: Synthesize nanoparticles from ginseng PS using microfluidic processing and 
characterize physicochemical properties and immunostimulatory activity in vitro. 
Nanoparticle synthesis was conducted to ascertain success in replicating the methodology 
reported by Akhter et al. and for further refinement. Modification of the methodology was 
performed to address the limitations of the aforementioned procedure and determine 
parameters which were previously not investigated by Akhter et al. The physicochemical 
properties – size and morphology – of the NPPS were examined as part of the modification 
and characterization process. 
 
Aim 2: Compare the penetration of bulk PS and NPPS across a membrane barrier to 
establish the influence of particle size on its permeability. The transport of NPPS and PS 
across cell/membrane barriers was investigated in vitro using a HaCaT keratinocyte 
monolayer. Quantification of the passage of bulk PS and NPPS across the monolayer was 
performed using a macrophage-stimulation-based biological assay. 
 
Aim 3: To determine whether the molecular weight of bulk PS influences the nanosizing 
process and immunostimulatory activity of NPPS. Size and morphology were examined as 
potential physicochemical properties influenced by the molecular weight of the substrate – 
PS. In vitro stimulation of RAW 264.7 macrophages was used as an experimental model 
to study immunostimulatory effect. 
 
Aim 4: To determine whether nanosizing bulk PS changes the mechanism underlying the 
immunostimulatory action. In vitro stimulation of RAW 264.7 macrophages was used as 
an experimental model. To determine whether TLR-mediated pathway was involved, two 
experimental designs were used: LPS-induced desensitized macrophages and use of a 
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Chapter 2  
 
Synthesis and characterization of 
physicochemical and biological properties of 
nanoparticles prepared from American 






North American ginseng has been widely reported to be immunomodulatory in vivo with 
both immunostimulatory and immunosuppressive effects1–3. They have been used to 
manufacture various nutraceuticals – a standardized dietary product – such as COLD-FX®️ 
and JamiesonTM Canadian Ginseng. The immunostimulatory effects are exerted by the 
ginseng polysaccharides (PS), which are derived from the cell wall of the ginseng root4. 
Ginseng PS are composed of complex chains of monosaccharides high in galactose (Gal), 
arabinose (Ara), galacturonic acid (GalA), rhamnose (Rha) and glucose (Glc)5. 
Polysaccharides are heterogeneous in nature due to a high degree of variation in the number 
and type of monosaccharide repeating units. As a result, a wide range of diversity is present 
in the solubility, hydrophilicity, molecular weight, structure and conformation of PS. 
Previous studies have shown that the biological effects of ginseng PS are mainly attributed 
to higher molecular weight PS rather than lower molecular weight PS6,7. 
 
Although diverse biological effects of PS have been reported, their effects are limited by 
its bioavailability. The large molecular size of PS and their hydrophilicity are both limiting 
factors to their absorption in the gastrointestinal tract6,8. These limitations to bioavailability 
can be potentially addressed by the application of nanotechnology to PS to modify particle 
size/polarity. It has been well-demonstrated that reducing the particle size of large and 
poorly permeable compounds to the nano-scale range improves its oral bioavailability9,10. 
A nanosizing methodology for ginseng PS has been developed by Prof. Lui and 
Charpentier's group to synthesize nanoparticles of ginseng PS (NPPS) by nanoprecipitation 
using continuous-flow microfluidics11. The resulting NPPS exhibited uniform and 
spherical characteristics with a narrow size distribution (20 ± 4 nm)11. In addition, the 
ginseng NPPS were monodispersed (i.e., uniform size and shape) with a higher crystallinity 
(i.e., higher order of structure) than the bulk material11.  
 
Similar to nutraceuticals, quality control of ginseng NPPS physicochemical properties is 
critical for ensuring safety and efficacy. For regular herbal products, phytochemical (i.e., 
bioactive compounds) profiling is the usual approach. However, to develop high-quality 
nanoparticles as nutraceuticals, a set of physicochemical parameters are usually used in the 
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evaluation process. In this study, we evaluated size and morphology, and measured the 
penetrative ability of the nanoparticles.  
 
Previously, Akhter et al. used fluorescent-labelled NPPS to study its disposition in skin 
after topical application to hairless mice. It has been shown that following treatment, NPPS 
passed into the dermis mainly through the transappendageal route (hair follicle, sweat 
gland) and dispersed throughout the dermis12. Furthermore, NPPS accumulated in dermal 
blood vessels and exhibited greater immunostimulatory activity than PS in samples 
collected from the skin12. Ginseng NPPS also demonstrated greater immunostimulatory 
activity in vitro compared to bulk PS11. In particular, ginseng NPPS increased tumor 
necrosis factor alpha (TNFα), interleukin (IL)-6, IL-1β and nitric oxide (NO) production 
in RAW 264.7 macrophages11. The authors concluded that the enhancement of biological 
activity of NPPS in macrophages might be related to its greater cellular uptake. NPPS 
accumulated within macrophages whereas bulk PS accumulated apically of the plasma 
membrane12. This apparent increase in cellular uptake of NPPS was speculated to be 
secondary to changes in surface chemistry and size rather than skeletal structure11.  
 
The increase in biological membrane permeability of NPPS is expected to enhance 
absorption from gastrointestinal tract and increase systemic bioavailability. This should 
also apply to the penetration of dermal barrier after topical application. The uptake of the 
nanoparticle depends on its physicochemical properties such as size or charge. 
Nanomaterials can be transported across the skin through transappendageal (diffusion via 
follicles/glands), paracellular and/or transcellular transport. Generally, nanoparticles that 
are transported transcellularly via receptor mediated-endocytosis or non-specific 
mechanisms13,14. The fate of the nanoparticle within a cell also varies depending on the 
compound, cell type and nanoparticle type14. Following endocytosis, the nanoparticles can 
be incorporated into endosomes, which could then be excreted or participate in the fusion 
with late endosomes that subsequently fuses with lysosomes14. The nanoparticles could 
also distribute in the cytoplasm or localize in the nucleus, mitochondria, ER or Golgi 





The amount of NPPS penetration was not measured by Akhter et al. due to difficulties 
quantifying the concentration of PS and its nanoparticle. Furthermore, there is a lack of 
technology for quantitation of PS polymers which do not have chromophoric moieties3. To 
address this, a biological assay was developed to estimate the amount of PS in biological 
samples. However, this assay is only viable under in vitro conditions in the absence of 
biological influences which could affect the specificity of the assay.  
 
In this study, penetration of NPPS and its bulk substrate (PS) across a cell monolayer was 
evaluated in order to provide a biological basis to explain the observed difference in 
deposition profiles between NPPS and bulk PS in dermal tissue in vivo following topical 
adminisration12. In order to verify the observed enhanced dermal penetration of NPPS in 
vivo, human keratinocytes (HaCaT) were used as an in vitro biological barrier to bulk PS 
and NPPS. The in vitro keratinocyte monolayer model – herein referred to as a monolayer 
model – was used to determine if NPPS penetrate the dermal barrier better than ginseng 
PS. The monolayer model is made up of a monolayer of confluent keratinocytes cultured 
on a trans-well insert with an established membrane integrity. The monolayer model was 
used to enable the examination of the penetration of a biological membrane in isolation 
without other biological influences.  
 
Since ginseng PS are known to be heterogeneous in size distribution, it is not certain how 
this factor influences the nanosizing process. To address this question, bulk PS was 
separated by ultrafiltration through different membranes of defined pore sizes into sub-
fractions of different molecular sizes. The PS sub-fractions were used as substrates for the 
preparation of NPPS, which was subsequently subjected to physicochemical and biological 
characterization in vitro. In summary, this chapter will address the modification of the 
microfluidic procedure, physicochemical and biological characterization of NPPS. We 
hypothesized that microfluidic processing of PS reduces particle size, improves 
permeability with heightened biological activity and that molecular size of PS is a 
determinant of resulting NPPS. In addition, we were able to develop an in vitro 
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keratinocyte monolayer model that was coupled with a bioassay for PS quantitation to 
evaluate the transport of NPPS.   
 
2.2 Experimental Procedure 
2.2.1 Materials 
Four-year-old Panax quinquefolius roots were collected in 2007 from five separate farms 
(Ontario, Canada) to prepare aqueous extracts which were then combined to produce a 
composite extract. The composite extract was provided by the Ontario Ginseng Innovation 
and Research Consortium for further extraction and isolation of ginseng PS. 
 
HaCaT human keratinocytes (CLS 300493) purchased from Cell Lines Services GmbH 
(CLS; Germany) were used to prepare an in vitro monolayer model and RAW 264.7 murine 
macrophages (ATCC TIB 67) provided by Dr. Jeff Dixon (Department of Physiology and 
Pharmacology, University of Western Ontario, Canada) were used for pharmacological 
studies. Dulbecco’s Modified Eagle’s Medium (DMEM) and Fetal Bovine Serum (FBS) 
(US origin) were purchased from Gibco Laboratories (USA). Lipopolysaccharides (LPS) 
from Escherichia coli (O111:B4) and Griess’ reagent (modified) were purchased from 
Sigma-Aldrich (Canada). 
 
2.2.2 Preparation of ginseng PS 
2.2.2.1 Crude PS ginseng. 
Dried ginseng root was grounded and soaked in nano-pure water (1:20) at 40 °C for 4 hrs. 
The extraction procedure was repeated three times and the extracts were combined, 
centrifuged and filtered to remove any particulate matters. The extract was concentrated 
via rotary evaporator (Buchi) under vacuum at 50 °C and lyophilized using a freeze dryer 
(Labconco). Ginseng PS fraction was precipitated by the addition of 95% ethanol in four 
sequential volumes, giving a final concentration of ethanol of 40% ethanol (v/v).  The 
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solution was centrifuged at 350 x g for 10 mins to obtain the precipitate (pellet). The pellet 
was further purified by dissolving the pellet in nano-pure water at approximately 1 g/mL 
and precipitated again with ethanol to remove remaining water-insoluble materials. The 
precipitate was lyophilized with a freeze dryer to obtain the crude PS ginseng extract. The 
crude PS extract was further processed by deproteinization using prepared Sevag reagent 
made with n-butanol and chloroform (1:4 ratio by volume). Briefly, powdered crude PS 
(10 g) was dissolved in nano-pure water (300 mL) and partitioned five times with 1000 mL 
of Sevag reagent. Once again, PS was precipitated from the solution by 95% ethanol and 
lyophilized via freeze dryer to obtain the bulk PS extract. 
 
2.2.2.2 Sub-fractionation of bulk ginseng PS by ultrafiltration. 
Ginseng PS were separated into molecular weight sub-fractions through ultrafiltration 
using Amicon® Ultra centrifugal filter devices (Millipore Sigma) (Fig. 2.1). Five 
Amicon® Ultra tubes with different pore sizes for a specified nominal molecular weight 
limit (NMWL) were used: 100,000, 50,000, 30,000, 10,000 and 3,000. Herein, NWML 
will be referred to in kilodaltons (e.g., 100 kDa) and Amicon® Ultra tubes as UF tubes. 
Briefly, PS were dissolved at a concentration of 1 mg/mL and sonicated for 1 hr. Five 
millilitres of the PS solution were placed into the 100 kDa UF tube and centrifuged at 4000 
x g in a swinging bucket rotor at 25°C for 30 mins. Subsequently, the precipitate was 
removed and labelled as the ≥ 100 kDa fraction while the filtrate was diluted to a final 
volume of 5 mL and transferred into the 50 kDa UF tube. The precipitate after 
centrifugation was labelled as the 50-100 kDa fraction. Once again, the filtrate was diluted 
to 5 mL and transferred into the 30 kDa UF tube. The precipitate was labelled as the 30-50 
kDa fraction. This was performed for a total of 10 times. 
 
After ultracentrifugation, the precipitates were combined and concentrated to 10 mL and 
transferred into a 15 mL centrifuge tube. Samples were frozen overnight and then 
lyophilized for 3-4 days to obtain ≥ 100 kDa, 50 - 100 kDa and 30 – 50 kDa PS. Herein, 
the fractions will be referred to as large (L-PS), medium(M-PS), small (S-PS), respectively. 




Figure 2.1. Schematic illustration of ultrafiltration procedure for separation of ginseng 
polysaccharides by nominal molecular weight limit (NWML). 
 
2.2.2.3 Synthesis of ginseng PS nanoparticles by microfluidic nanoprecipitation. 
NPPS and sub-fractionated NPPS were prepared from bulk PS and sub-fractionated PS 
respectively by a continuous microfluidic system using T-junction geometry (Fig. 2.2). 
Stainless steel T-junction or Micro-TEE (Upchurch Scientific) was used, with an inner 
diameter of 1500 µM. The microfluidic setup consisted of two infusion syringe pumps, 
Legato 1100 and Legato 2200 (KD Scientific) attached to the arms of the T-junction. The 
first pump attached to Arm 1 was used to infuse the solvent which was an aqueous solution 
of deproteinated ginseng PS. This PS solution was prepared using nano-pure water at a 
concentration of 0.55 g/mL followed by ultrasonication. The second pump attached to Arm 
2 was used to pump the anti-solvent (acetone; 100%; HPLC grade). The solvent and anti-
solvent were infused at a ratio of 1:20. Specifically, the solvent was infused at 0.01 mL/min 
and the anti-solvent at 0.2 mL/min. Attached to Arm 3 is PEEK tubing with an outer 
diameter of 1500 µM and an inner diameter of 75 µM (Upchurch Scientific). Arm 3 was 
directed towards a reservoir containing 15 mL of acetone, which is continuously mixed 
with a magnetic stirrer at room temperature to prevent sedimentation. The dispersion 
containing synthesized NPPS was collected from the reservoir and concentrated to remove 
excess acetone and centrifuged at 350 x g for 15 mins to sediment the precipitate. The 
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precipitate was recovered by removing the supernatant by vacuum suction. The precipitate 
was resuspended and then combined into a composite batch. The batch was concentrated 
and centrifuged again prior to lyophilization by freeze drying. The lyophilized powdered 
ginseng NPPS was stored at 4 °C before ready for experimentation. 
 
 
Figure 2.2. Experimental setup of continuous microfluidics system for the preparation of 
ginseng polysaccharide nanoparticles. Pump 1: Solvent phase (H2O) containing ginseng 
polysaccharide. Pump 2: Anti-solvent (acetone). Adapted from Akhter et al.12. 
 
2.2.3 Physicochemical characterization of ginseng PS nanoparticles  
The size and morphology of nanomaterial samples were examined using transmission 
electron microscopy (TEM) (Philips CM10). No stain was used for the samples. 
Nanoparticles for TEM imaging were prepared by dispersing samples in acetone. The 
dispersion products were deposited onto formvar-coated copper grids. TEM images were 
also measured by ‘ImageJ’ software to assess the size distribution of the sample. The 
contrast of TEM images was adjusted to assist visualization and measurement of particles.  
 
The size distribution of the nanomaterials was measured by dynamic light scattering (DLS) 
(Malvern Zetasizer Nano ZS(R)) instrument; Nano S model ZEN 1600, Malvern, Orsay, 
Aq. solution of ginseng  
PS (0.55 mg/mL) 
@ 0.01 mL/min  
Water-acetone system  
Acetone @ 
0.2 mL/min  
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France). Briefly, the PS samples were dispersed in water and then ultrasonicated for 5 mins 
to assist in the dispersion. Dispersed samples were loaded into a disposable polystyrene 
sizing cuvette (DSTS0012) and backscattering measurements (173°) was collected at room 
temperature (25°C) at a measurement position of 4.65 mm. The sizing cuvette containing 
the sample was allowed to equilibrate for 30 sec before 3 consecutive acquisitions that were 
averaged over 2 sec were recorded.  
2.2.4 Biological analyses 
2.2.4.1 Cell culture. 
Spontaneously transformed aneuploid immortal human keratinocytes (HaCaT) and 
Abelson murine leukemia virus transformed macrophages (RAW 264.7) were cultured in 
DMEM supplemented with 10% FBS and 1% penicillin/streptomycin. Cell cultures were 
maintained at 37℃ in a humidified incubator with 10% CO2. The concentration of CO2 
was used in accordance with the concentration of sodium bicarbonate (3.7 g/L) contained 
in the media to maintain a physiological pH of ~ 7-7.4. HaCaT cells were passaged every 
8-10 days at approximately 80% confluency. Cell culture media were changed biweekly. 
RAW 264.7 cells were passaged every 3-4 days at approximately 80% confluency. Cell 
culture media was changed one day prior to passage. Cell viability was determined by 
trypan blue dye exclusion test, which is based on the permeability of non-viable cells to 
the dye. Cell cultures were tested for mycoplasma contamination using the MycoAlert® 
Mycoplasma Detection Kit (Lonza). None of the cell cultures used were tested positive. 
 
2.2.4.2  Stimulation of macrophage function in vitro. 
Immunostimulatory activity of PS and NPPS was investigated using RAW 264.7 murine 
macrophage cells. Macrophage cells were seeded during the logarithmic phase (~80% 
confluency) into 96-well tissue culture plates at a density of 1.5 x 105 cells per well and 
incubated at 37 ℃ and 10% CO2. RAW 264.7 cells were treated with PS and NPPS for 24 
hrs. Treatment concentrations of PS and NPPS were at 50, 100, 200 and 300 µg/mL. At 24 
hrs the cell culture supernatant was removed to measure NO production by the 





To study the effects of substrate molecular weight on the immunostimulatory effects of 
sub-fractionated NPPS samples (i.e., L-NPPS, M-NPPS, S-NPPS), RAW 264.7 
macrophages were treated with 0 – 200 µg/mL of sub-fractionated NPPS. In addition, cells 
were treated with 0 – 200 µg/mL of sub-fractionated ginseng PS (i.e., L-PS, M-PS, S-PS) 
and compared with ginseng NPPS to investigate the effects of nanosizing on its 
immunostimulatory activity. At 24 hrs the cell culture supernatant was removed to measure 
NO production by the macrophages. 
 
2.2.4.3 In vitro model for measurement of penetration of PS and NPPS across 
monolayer. 
The purpose of this model was to measure the penetration of ginseng PS and NPPS across 
a viable cellular membrane with biological integrity, which may provide an estimation of 
bioavailability. A keratinocyte monolayer was used to simulate a dermal barrier. The in 
vitro skin model consists of keratinocytes cultured on polyethylene terephthalate (PET) 
trans-well inserts (1 µM pore) placed within a 24-well plate (Fig. 2.3). HaCaT cells were 
seeded at a density of 5.0 x 104 cells/ insert. Inserts were immersed in cell culture media 
and incubated until confluency. Cell culture media in the apical and basolateral 
compartment were changed biweekly. Three days post-confluency, transepithelial 
electrical resistance (TEER) of the keratinocyte monolayer was measured with EVOM2 
STX2 electrodes and monitored to ensure membrane integrity. Monolayers with a TEER 
less than 50 Ω*cm2 attributed to low membrane integrity were discarded. The threshold 
was determined based on the study conducted by Ferreira et al., and data from preliminary 




















Figure 2.3. Schematic of penetration model. HaCaT keratinocyte monolayers were 
cultured on 1 µM transwell inserts (polyethylene terephthalate). Transwell inserts were 
immersed in cell culture media inside wells of a 24-well plate. 
 
Both the apical and basolateral compartments were filled with 1000 µL of culture media. 
Experiment to evaluate sample penetration over time across the keratinocyte monolayer 
into the basolateral compartment was performed by replacing the media in the apical 
compartment with 1000 µL of ginseng NPPS or PS (300 µg/ mL). 1000 µL of conditioned 
media was removed from the basolateral compartment at 6, 12 and 18 hrs for quantitation 
of PS and NPPS. At each time point of sampling, an equal volume of fresh media was 
added for replacement. Herein, samples obtained from the basolateral compartment will be 
referred to as conditioned media.  
 
To evaluate the influence of concentration on the penetration of samples across the 
keratinocyte monolayer, the apical compartment was treated with media (1000 µL) 
containing 0, 50, 100, 200 or 300 µg/mL of ginseng NPPS or PS for 24 hrs. Thereafter, 
conditioned media were removed from the basolateral compartment and stored until 







2.2.4.4 Bioassay for quantitation of PS and NPPS 
In the absence of a chemically-based methodology to quantify PS and NPPS, a bioassay 
that was based on the stimulation of NO production by RAW 264.7 macrophage was 
developed to quantify the presence of PS and NPPS in the basolateral compartment 
(Appendix A1). A standard curve based on stimulation of plated macrophages NO 
production 24 hrs following treatment with 0, 50, 100, 200 and 300 µg/mL of ginseng PS 
or NPPS was prepared. Nitric oxide was estimated indirectly by measuring nitrite 
concentration by the Griess’ assay. The standard curve was constructed as a semi-log plot 
from nitrite concentration (dependant) and treatment concentration (independent) (Fig. 
A.1). The standard curve was subsequently used to calculate the unknown sample 
concentrations. 
 
To determine the concentration of PS or NPPS found in the conditioned media collected 
from the bio-membrane penetration study, experimental samples (200 µL) were added to 
the macrophage cultured in 96-well plates. The accumulation of NO in the culture media 
over 24 hrs was determined by the Griess’ reagent test. The concentration of PS or NPPS 
in the samples was estimated from the PS or NPPS standard curve, respectively. 
 
2.2.4.5 Quantification of NO production 
Nitric oxide production was measured by colorimetric detection of the presence of nitrite 
ion in the media. Nitrite is a final product of the NO oxidation pathway. Nitric oxide in 
culture supernatants was determined using modified Griess’ reagent containing 0.5% 
sulfanilic acid, 0.002% N-1-naphthyl-ethylenediamine dihydrochloride and 14% glacial 
acetic acid (Sigma-Aldrich, USA). Briefly, 50 µL of Griess reagent was added to 50 µL of 
culture supernatant and incubated away from light at room temperature for 15 mins. 
Absorbance at 540 nm wavelength was measured using uQuant microplate reader (Biotek 
Inc.). Wells containing air bubbles which distort measurements were excluded. Nitrite 




2.2.5 Statistical analysis  
Data are presented as mean ± standard error of the mean (SEM). The two-way analysis of 
variance (ANOVA) followed by Bonferroni’s post hoc test was used for the comparison of 
means between treatment groups. The one-way analysis of variance (ANOVA) followed 
by Dunnett’s post-hoc was used for the comparison of means with the untreated control 
(vehicle). Statistical analysis was performed using GraphPad Prism 6 software (San Diego, 
CA). Values P < 0.05 compared between treatment groups were considered statistically 
significant. 
 
2.3 Results and discussion 
In this study, crude ginseng PS was isolated from a water extract of 4-year-old Ontario-
grown American ginseng roots by precipitation with 40% ethanol with a yield of  ~ 9 ± 1 
% by dry-weight of root sample. This is consistent with what was reported in other studies6. 
Ginseng NPPS were prepared from bulk PS based on the microfluidic methodology 
designed by Akhter et al.11 (see Fig. 2.1.). This procedure was modified successfully (i.e., 
substrate concentration) to address susceptibility for sample build-up in the T-junction and 
PEEK tubing. Nanosizing ginseng PS from 15 batches provided a yield of ~ 95% by weight 
relative to the substrate (i.e., bulk PS) weight. Subsequently, the resulting nanoparticles 
were characterized physicochemically and compared with the ginseng NPPS 
characteristics reported by Akhter et al.11. Penetration of ginseng NPPS across the dermal 
barrier was investigated to provide a biological basis for the apparent increase in deposition 
of ginseng PS into the dermis in vivo12. The influence of PS characteristics – namely its 
molecular weight – on the characteristics of the nanoparticles and its potency were also 
studied. The results of these studies were presented below. 
2.3.1 Morphology and size distribution of ginseng PS and NPPS 
Transmission electron microscopy (TEM) was performed on a NPPS composite sample 
prepared from 15 batches and a comparable bulk PS sample was used as a reference. As 
shown in Fig. 2.1a, bulk PS has an indistinct and unresolved structure with no regular 
nanomorphology. The unclear TEM micrograph is expected as one of the challenges 
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associated with the characterization of PS structures is that they have poor electron density, 
making it difficult to obtain high-resolution TEM images16. Furthermore, no stains were 
used during TEM preparation of PS samples. PS macromolecules and supramolecules 
(higher-leveled structures of macromolecules) are present as indicated within the 
micrographs by the arrows. Furthermore, agglomerates of PS were observed in the TEM 
micrograph. The TEM micrograph indicates that the PS supramolecules were amorphous 
and irregular in shape. Preliminary studies (data not shown) investigating the effect of 
aggregation has shown that the bulk PS would aggregate at concentrations past the 
solubility threshold (i.e., ~ 0.75 mg/mL) and rapidly sediment. The TEM micrograph of 
the nanosized ginseng PS (Fig 2.4b) showed that the prepared nanoparticles were much 
more uniform and within the nano-size range (< 100 nm). Particle size analysis of the TEM 
micrograph using “ImageJ” software of Fig. 2.4b gave a molecular distribution of 
approximately 12 – 26 nm in diameter with an average size of 19 nm (Fig. 2.5). The 
nanoparticles were also distinctly separated from one another and did not agglomerate. 
From these images, it is apparent that the morphology of ginseng NPPS was much more 
regular in size compared to PS, with spherical and smooth surfaces. The nanomorphology 
of these ginseng NPPS was similar to the characteristics of the ginseng NPPS reported by 
Akhter et al. Briefly, the authors also reported monodispersed nanoparticles that were 
unimodal and spherical in shape. These nanoparticles synthesized by Akhter et al. were 










Figure 2.4. Transmission electron microscopy (TEM) micrograph of (a) bulk PS and (b) 
NPPS. Ginseng NPPS were synthesized by nanoprecipitation using microfluidics with a 
1:20 flow rate ratio and 75 µm (inner diameter) PEEK tubing. Samples were dispersed in 
acetone and TEM was performed using Philips CM10 without using any stains. Arrow 1: 

















Figure 2.5. Size distribution of ginseng NPPS prepared by nanoprecipitation using 
microfluidics. Particle size is in diameter and was measured by ImageJ Software. Data 
presented was from a representative experiment. 
 
In addition to TEM, the size distribution of the prepared NPPS was characterized using 
dynamic light scattering (DLS). As a comparison, bulk PS was also analyzed via DLS. 
Two separate size distributions were observed with bulk PS at approximately 90 – 140 nm 
and 820 – 1800 nm in diameter, with a mean peak of 110 nm and 1200 nm, respectively 
(Fig. 2.6a). The small and large size components had an area under the curve (AUC) of 
14% and 86%, respectively. In contrast, NPPS had a single mean particle size of ~34 nm 
in diameter was measured (Fig. 2.6b). The measured particle size range of 28 – 44 nm 
corroborates with the TEM results. Results from the DLS indicate the hydrodynamic 
diameter of these particles in water based on a large number of molecules using light 
scattering. In comparison, TEM measurements from ImageJ (Fig. 2.5) use only a small 
number of measurements (i.e., ~ 100). Both results (Fig. 2.5 and Fig. 2.6) indicate 
successful nanoparticle formation (i.e., < 100 nm in diameter). TEM samples are dispersed 
and subsequently dried on a copper grid whereas DLS samples are dissolved in a solvent. 
51 
 
With this consideration, the difference in size distributions indicates NPPS interact to a 
small degree non-covalently when in solution.  
 
Figure 2.6. Dynamic Light Scattering of (a) ginseng PS and (b) NPPS using Zetasizer 
Nanosizer. Size distribution is presented as the diameter of the particles in nm and 
displayed as a function of intensity. Analysis was performed three times. Data presented 
was from a representative experiment. µ = mean; σ = standard deviation. 
 
The parameters used for microfluidic processing of ginseng PS in the study conducted by 
Akhter et al. was similar to the parameters used in this current study, namely the anti-
solvent to solvent ratio, flow rate, MicroTEE thru-hole, and PEEK tubing size. The main 
difference between these two procedures was the concentration of substrate used (0.55 
mg/mL) and the technique to recover the product. The concentration of the substrate was 
not reported in the reference procedure. The concentration of the substrate used in the 
σ = 2.2 nm 
σ = 11.3 nm 
µ = 1199.0 nm 
µ = 34.0 nm 
µ = 107.4 nm 





procedure was also modified to allow for higher success rates (i.e., no clogging/ system 
errors) and greater yields. Based on the results (Fig 2.5), these alterations to the 
microfluidic procedure did not seem to greatly affect the average size (± 1 nm) or 
morphology of the nanoparticle compared to those reported by Akhter et al. Thus, the 
ginseng NPPS (15 batches) synthesized for our study demonstrated reproducibility (i.e. 
size and morphology) of the aforementioned nanoparticles in the study conducted by 
Akhter et al.11. 
 
Nanoprecipitation of bulk PS was demonstrated by Akhter et al. to not affect its chemical 
structure but increases its crystallinity11. Although there is higher structural order, the 
NPPS are still amorphous. Furthermore, the nanoparticles were formed due to interactions 
between the solvent and anti-solvent at the channel junction rather than through reactions 
with the acetone17,18. The chemical structure of a substrate is not typically altered following 
nanoprecipitation unless compounds, markers or tags are conjugated to the substrate and if 
the substrate reacts with the solvents. In a study conducted using nanoparticles prepared by 
bottom-up nanocrystallization (i.e., probe-sonication controlled precipitation), the 
chemical structure of the substrate compound did not change following size reduction19. 
This was attributed to changes in the crystalline structure and no functional changes were 
observed19. In another study, Zhou et al. reported that hydroxycamptothecin (HCPT: 
C20H16N2O5) nanorods and nanoparticles prepared by nanoprecipitation did not exhibit 
differences in its chemical structure compared to bulk HCPT20. These functionality 
changes could be attributed to physicochemical changes.  
 
2.3.2  Biological characterization of NPPS 
2.3.2.1   Stimulation of macrophage function. 
To investigate the pharmacodynamics of the ginseng NPPS with reference to bulk PS, 24-
hr response in cultured murine macrophages was examined. Ginseng PS and NPPS 
treatment showed dose-dependent stimulation of NO production up to 200 µg/ml and no 
further increase was observed with a higher dose (Fig. 2.7). The stimulatory response was 
53 
 
significantly higher with NPPS treatment by approximately 35% at all concentrations. It 
should be noted that the maximum response to NPPS was similar in magnitude to that 
induced by the positive control (1 µg/ml LPS) (data not shown). Based on the dose-
response data, the respective EC50 values of 73.84 μg/mL and 93.12 μg/mL for NPPS and 
PS have been estimated. This provides further evidence of elevated potency with NPPS.  
 
Figure 2.7. Immunostimulatory effects of ginseng PS and NPPS on macrophage NO 
production. Macrophages were treated with 0-300 µg/mL of NPPS and PS for 24 hrs. Three 
independent experiments were performed in triplicates. Data are presented as mean ± SEM. 
Datasets were statistically analysed by two-way ANOVA followed by Bonferroni’s post 
hoc test. * Values P < 0.05 compared to the control were statistically significant. # Values 
< 0.05 compared between treatment groups were statistically significant.  
 
Nitric oxide as an inflammatory mediator has been widely reported to be involved in the 
immunomodulatory activity of plant PS21–23. The up-regulation of NO production observed 
with ginseng PS treatment was consistent with the results reported previously in the 
literature4,24. The increase in NO production by NPPS was also consistent with the study 
conducted by Akhter et al.11. Both studies show that NPPS are more effective 
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immunostimulating agents compared to ginseng PS. The authors also reported enhanced 
TNFα, IL-1β and IL-6 production induced by NPPS11. This suggests that the apparent 
enhancement is not limited to stimulation of NO production but possibly related to the NF-
κB pathway12. Perez et al. recently synthesized another type of ginseng nanoparticle and 
studied their pharmacological effects25. In this case, gold/silver salts and whole ginseng 
berry extract (GBE) instead of pure PS were used. The main phytochemicals present in 
ginseng berry extract are PS, phenolics, flavonoids, tannins, and ginsenosides. 
Characterization of the resulting nanoparticles suggested that ginsenosides, acidic 
polysaccharides, polyphenols and reducing sugars were capped onto the gold or silver 
nanoparticles25. These gold or silver core GBE nanoparticles were non-toxic and had 
enhanced pharmacological effects (e.g. free radical scavenging activity) compared to bulk 
GBE25. Although the nanoparticles from both studies are different, both indicated enhanced 
bioactivity following reduction of hydrodynamic volume25. 
 
Various other nanoparticles have similarly demonstrated enhanced biological effects 
compared to its corresponding substrate, which includes enhanced immunological, 
bactericidal or toxic effects. Morones et al. reported that the bactericidal effects of silver 
nanoparticles were improved with decreasing size due to the increased surface area 
interaction26. In a different study, zinc oxide (ZnO) nanoparticles exhibited enhanced 
antimicrobial effects compared to bulk ZnO27. Padmavathy et al. also reported that the 
enhancement of effect was inversely related to its size27. Although in each case different 
methodology and materials were used, the enhancement was consistently attributed to the 
change in size and surface chemistry because of the absence of functional changes to the 
molecules. 
 
2.3.2.2 Penetration of NPPS across keratinocyte monolayer model in vitro. 
2.3.2.2.1 Validation of the monolayer system. 
Monolayer models have been regularly used in the pharmaceutical industry and in 
academic research institutions to estimate and predict intestinal drug absorption in vitro 
and study the mechanisms underlying drug transport. These models are often used to 
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identify relevant drug transporters, potential drug absorption complications, and if the drug 
is actively or passively transported. In these models, cell monolayers (e.g., Caco-2 or HT29 
intestinal epithelial cells) are cultured on permeable inserts to simulate a cellular 
barrier28,29. Various models have also been developed to study drug transport across other 
barriers, such as the blood-brain barrier or dermal barrier. Examples of these models 
include human cerebral microvascular endothelial cells (hCMEC/D3) or immortalized 
human keratinocytes (HaCaT), respectively30,31. In this current study, we used a HaCaT 
monolayer model to study the transport of ginseng PS and NPPS across cultured 
keratinocyte monolayer. Transepithelial Electrical Resistance (TEER) was used to 
ascertain the functional integrity of monolayers in this study30. Typically, higher resistance 
is measured when the monolayer has high membrane integrity (i.e., tight junctions) due to 
the interference of the monolayer between electrical probes. A lower TEER threshold (> 
50 Ohms*cm2) was used to select intact keratinocyte monolayers. The lower threshold 
represents the baseline TEER to determine membrane integrity.  Moreover, as shown in 
the data presented below, bulk PS, which are known to have limited systemic 
bioavailability also showed limited, if any, penetration. This provides further evidence of 
a functional monolayer system. 
 
To determine the penetration of a test compound across a monolayer, the change in its 
concentration in the compartment(s) as a function of time has to be measured. The 
quantification of a test compound is typically performed using chemical detection 
technology. However, quantification of plant PS is difficult because of its lack of 
chromophoric moieties. There is also a lack of effective chromatographic techniques to 
provide resolution to ginseng PS which are known to be heterogeneous in molecular size. 
Akhter et al. has developed a methodology to label PS with a fluorescent tag (5-FTSC) for 
bioimaging but has many limitations for quantitative analysis12. A bioassay was used in 
this study to measure PS concentration (Fig. A.1). This bioassay was developed based on 
the initial characterization study of the immunostimulation of macrophages by ginseng PS 
and NPPS as described earlier (Fig. 2.7). A standard curve was prepared by measuring 24-
hrs NO production by RAW 264.7 macrophages with 50 – 300 μg/mL concentrations of 
ginseng PS and NPPS (Fig. A.1). The PS and NPPS standard curves are sensitive to sample 
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concentrations between the stimulation conditions (50 – 300 μg/mL). Although the 
bioassay can estimate sample concentration based on its degree of macrophage stimulation, 
other stimulatory factors may be present in the sample which may have been released by 
the keratinocytes that could interact with the sample. If that is the case, there may be an 
overestimation of the result, affecting the specificity of the assay. Despite the limitations, 
this monolayer model has allowed us to compare the penetrations of PS and NPPS and test 
our hypothesis.  In view of our failure to monitor changes in membrane integrity at the end 
of the penetration experiment, we could not rule out the induction of monolayer toxicity 
(dysfunction) rendering a false-positive-evidence for penetration. 
 
2.3.2.2.2 Penetration of ginseng PS and NPPS across monolayer. 
To determine whether the keratinocyte monolayer is a barrier to PS and NPPS, a solution 
of PS or NPPS (300 μg/mL) was added to the apical compartment and their accumulation 
in the basolateral compartment over the course of 18 hrs was determined by a bioassay. As 
shown in Fig 2.8, no PS was detectable in the basolateral compartment over the 18-hr 
period (PS detection limit: 50 μg/mL). In contrast, significant levels of NPPS were detected 
at the 18-hr sampling time-point but not at earlier time-points. This apparent abrupt 
increase in penetration may be attributed to the low degree of sensitivity of detection. The 
sensitive concentration for NPPS was 50 μg/ml; as compared to ~ 110 μg/ml recorded for 
NPPS at 18 hrs. The accumulation at 12 hrs may have been near but below the minimum 
sensitive concentration. If so, the increase observed would be comparably small but still 
significant. Despite the low sensitivity, results show that it is likely that the keratinocyte 
monolayer was a barrier for PS, but not NPPS. The marked increase in penetration at 18 
hrs and lack of prior detectable penetration could potentially be attributed to a loss of 
membrane integrity over time induced by NPPS. Moreover, the loss of membrane integrity 















Figure 2.8. Accumulation of ginseng PS and NPPS in the basolateral compartment over 
periodic 6-hr intervals. RAW 264.7 cells were treated with conditioned media (300 µg/mL 
PS or NPPS treatment) collected from the basolateral compartment at 6, 12 and 18 hrs for 
PS or NPPS quantitation. Concentration was estimated from 24-hr macrophage NO 
production using respective standard curves. The sensitivity of bioassay was 50 - 300 
µg/mL; therefore, concentrations below 50 µg/mL were undetectable. Experiments were 
performed in triplicates and the data are presented as mean ± SEM, n =3. * indicated time-
dependent differences in accumulation; P < 0.05; two-way ANOVA).  
 
In view of the observed accumulation of NPPS (300 µg/mL) over time across the 
keratinocyte monolayer, an additional experiment was conducted to determine whether the 
penetration was dependent on the concentration. This may provide additional information 
regarding the nature and mechanism of penetration. Four concentrations of ginseng PS and 
NPPS were used (50, 100, 200, 300 μg/mL) and the result was expressed based on the 

























As shown in Fig. 2.5, the 24-hr accumulation of PS was insignificant even at the highest 
concentration tested (values being below the detection limit of 50 μg/mL). Significant 
accumulation of NPPS was detected at treatment concentrations of 200 and 300 μg/mL, 
but not at lower concentrations (Fig. 2.9). It was estimated that at 200 μg/mL of NPPS, 
approximately 65% of the NPPS load penetrated the monolayer into the basolateral 
compartment over the 24-hr period. However, the accumulation was not dose-dependent 
between 200 and 300 μg/mL. This may suggest that the penetration of NPPS across the 
monolayer was reaching saturation at higher concentrations.  
 
 
Figure 2.9. Basolateral concentration of PS and NPPS after 24-hr treatment. Conditioned 
sample was obtained from the basolateral compartment after 24-hr treatment to the 
keratinocyte monolayer model. The model was treated with 0-300 μg/mL of NPPS or PS. 
Three independent experiments were performed in triplicates and the data were presented 
as mean ± SEM. Datasets were statistically analysed by two-way ANOVA followed by 





The observed enhancement of ginseng NPPS penetration of the keratinocyte monolayer is 
consistent with our previous in vivo observation following topical application in hairless 
mice (Akhter et al.)12. Furthermore, results are consistent with the poor permeability of 
other plant PS that has been reported8. The apparently limited penetration of PS is likely 
due to the lack of passive transport pathways which are mainly restricted by its large 
particle size. Typically, large particles or agglomerates are engulfed by phagocytosis (> 0.5 
μm) leading to downstream lysosomal degradation32. In addition, PS may also undergo 
receptor-mediated endocytosis, pinocytosis and macropinocytosis32. These pathways target 
particles to early endosomes and may result in downstream basolateral transcytosis or 
degradation14. If the metabolites of these degradative pathways are not immunologically 
active, the bioassay would not quantify PS that undergo transport by these mechanism(s), 
which leads to an underestimation of PS penetration.  
 
We have not studied the basis for the apparent high penetration of NPPS across 
keratinocyte monolayer. However, NPPS may undergo several modes of transport across 
membrane/cellular structure: (1) passive diffusion; (2) paracellular transport - nano-scale 
molecules penetrate basolaterally across the keratinocyte monolayer in between cells due 
to their extremely small size (< 50 nm); and (3) transcellular pathway (active transport) - 
endocytotic uptake by keratinocytes followed by basolateral release. This may include 
pinocytosis (non-adsorptive or adsorptive), macropinocytosis and/or receptor-mediated-
endocytosis. (< 0.5 µM)14,32. It is likely that more than one of these processes may have 
occurred concurrently. The relative contributions of these mechanisms may depend on 
several factors, including nanoparticle size, lipophilicity and concentration. The last factor 
is dynamic and is expected to change with exposure time. Agglomeration of NPPS in 
solution can also affect the transport of the nanoparticle.  
 
Our physicochemical analysis showed a reduction in particle size of PS corresponding to a 
reduction in hydrodynamic volume (Fig 2.5 & 2.6), which is consistent with what is 
reported in the literature11. The reduction of particle size should enable passive transport 
of PS particles across the monolayer which is limited by the surface charge and size of the 
particles. In a recent publication, nano-formulations of beta-carotene exhibited greater 
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kinetic saturation solubility and dissolution compared to bulk beta-carotene33. The nano-
formulation was also demonstrated to be taken up by HaCaT keratinocytes faster than the 
poorly-soluble bulk-formulations33. In addition, the resorption of the nano-formulations of 
beta-carotene decreased with increasing crystalline size of beta-carotene33. In cases like 
ginseng NPPS where the nanoparticles consist of the drug itself (i.e., substrate only), 
smaller particle size was the main factor which increased bioavailability34,35. Megace ®️ ES 
(Par) and TriCor®️ (Abbot) are recent nano-pharmaceutical examples of such nanoparticle 
drugs which exhibited enhanced bioavailability34,35. Although different nanomaterials have 
different characteristics, the size was a common factor which has been shown to increase 
penetration across barriers36. The decrease in particle size of bulk PS following 
nanosization also increases surface-area-to-volume ratio37. A larger surface-area-to-
volume ratio exhibits greater solubility, faster dissolution, and allows for greater interaction 
with the cellular membrane38–40. Therefore, passive transports are more likely. 
 
It is evident that the particle size of NPPS also plays a role in active transport. Li et al. 
showed that the transport of lipid nanoparticles across Caco-2 monolayers was dependent 
on size41. Transport of these nanomaterials was found to occur mainly by endocytosis and 
smaller lipid nanoparticles exhibited higher permeability41. The attainment of high relative 
basolateral/treatment NPPS concentration (> 65%) and the evidence of apparent saturating 
transport characteristic at high concentration is suggestive of the involvement of active 
transport mechanisms. In a paper evaluating the cellular uptake of chitosan nanoparticles 
in Caco-2 cells, the authors reported change from extracellular interaction of chitosan to 
cellular internalization via clathrin-mediated endocytosis following nanosization42. 
Chitosan nanoparticles were also reported to be internalized via adsorptive endocytosis, 
macropinocytosis and caveolae-mediated endocytosis43,44.  
 
Various factors may have influenced the apparent detection of PS or NPPS accumulation 
in the basolateral compartment. Firstly, as pointed out earlier in the validation of the model, 
the bioassay used for measuring PS and NPPS lacks specificity in that it registers all 
immunostimulatory activity. In this regard, the induction of keratinocyte monolayer by 
NPPS to produce immunostimulatory factors and the subsequent release into the 
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basolateral compartment could lead to an apparent increase in NPPS penetration resulting 
in an over-estimation of penetration. Obviously, this is not true for PS as no penetration 
was detected. Secondly, the loss of the membrane integrity due to PS or NPPS toxicity 
could not be ruled out as we did not assess this parameter at the end of the experiment. This 
could have been measured by evaluating the TEER of the monolayer at the conclusion of 
the penetration study. As pointed out by Konishi et al., lower integrity of the monolayer 
may result in higher permeability of the membrane28. Therefore, the limitations of the 
bioassay and experimental design allow for the possibility that nanosizing bulk PS did not 
enhance its penetration. Instead, potential NPPS toxicity to the monolayer affected the 
viability and disrupted tight junctions thereby affecting its ability to act as a barrier to 
NPPS.  
 
Increasing the penetration of a compound across a monolayer clinically translates to 
increasing its bioavailability45–47. The monolayer model used in the present study provides 
evidence to support the hypothesis that nanosizing PS enhances its penetration across a 
membrane barrier. This conclusion is based on assumptions that: (1) there was no cellular 
metabolism of PS; (2) NPPS did not affect the integrity of the monolayer, and; (3) NPPS 
did not interact with keratinocytes and induce a release of stimulatory factors. 
 
2.3.3  Effect of substrate molecular weight on nanosization 
2.3.3.1 Morphology and size distribution of NPPS prepared from ginseng PS of 
different molecular sizes. 
As mentioned earlier, ginseng PS are quite heterogeneous with molecular weights ranging 
from as high as 2,000 kDa to as low as 3.1 kDa48,49. This raises the question of whether this 
parameter would influence the responsiveness to the nanosizing process as well as the 
quality and biological activity of the resulting NPPS. The other issue is whether the 
heterogeneity of the PS sample would be able to facilitate the process. Three different 
substrates were obtained by ultrafiltration of PS into three molecular weight sub-fractions: 
≥ 100 kDa, 50 - 100 kDa or 30 – 50 kDa. Herein, they will be referred to as sub-fraction L, 
M and S, respectively. This separation was based on the pore size specification of 
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membranes used in the filtration system (see Fig. 2.3). The average yields for the separation 
of bulk PS were as follows: 54%, 27% and 14% for fraction L, M and S, respectively. The 
remaining 5 % fraction (< 30 kDa) was not used in the subsequent study. The yield of the 
NPPS synthesized from these fractions averaged approximately 94% and similar to the 
yield of NPPS prepared using bulk PS. 
 
The size and morphology of the L-NPPS, M-NPPS and S-NPPS were characterized by 
TEM (Fig. 2.10i) and then processed by “ImageJ” software (Fig. 2.10ii). TEM image 
showed that the nanoparticles obtained from the three sub-fractions were spherical and 
monodispersed. As shown in Fig. 2.6ii, the NPPS obtained from the sub-fractions S, M and 
L had a mean diameter of 12 nm, 16 nm and 16 nm, respectively. S-NPPS had a relatively 
smaller size distribution than other two NPPS – M-NPPS and L-NPPS.  In general, the size 
































Figure 2.10. (i) Transmission electron microscopy (TEM) and (ii) size distribution of 
NPPS prepared using (a) 30-50 kDa, (b) 50-100 kDa and (c) >100 kDa ultracentrifuged PS 









flow rate ratio and 0.020-inch PEEK tubing. TEM was performed using Philips CM10 and 
acetone as a dispersant. The scale is at 100 nm.  
 
Separation of bulk PS into molecular weight sub-fractions reduces its heterogeneity in 
molecular weight. Compared to conventional polymers, PS polymers are not only 
heterogeneous due to differences in monomeric repeat number, but also in its composition. 
Results revealed that using more homogenous substrates (L-PS < M-PS < S-PS) produced 
NPPS with similar yields but with smaller particle sizes compared to using a bulk 
heterogeneous PS. Among the NPPS produced from the sub-fractions, the small molecular 
fraction resulted in smaller NPPS. It is possible that restricting the heterogeneity of the 
substrate enhances the order during nucleation, thereby increasing crystallinity. If the 
substrate is more homogenous, it is possible that nucleation of individual PS molecules 
during nanoprecipitation would be more uniform because there is less variability in 
molecular weight constrained by separation into molecular weight sub-fractions. 
Conversely, nucleation of highly heterogeneous PS would result in variable crystallization. 
To investigate this claim, further analysis such as X-ray diffraction (XRD) would be 
needed to determine crystallinity between fractionated NPPS. Differences in viscosity and 
sedimentation velocity between molecular weight fraction of PS may also contribute to the 
apparent shift in size. These two factors could potentially influence the agglomeration of 
PS. 
 
The influence of polymeric molecular weight on nanomorphology and size has been 
reported previously in the literature. Polymeric molecular weight was observed to decrease, 
increase or have no effect on particle size in different studies50–52. Although this has been 
demonstrated, microfluidic processing of ginseng PS differs in lacking an additional 
stabilizer or polymer. Using microfluidics, Akhter et al. demonstrated that similar factors 
compared to conventional nanoprecipitation influenced nanoparticle characteristics11. 
These factors include the flow-rate of solvents and anti-solvents as well as the water-to-
acetone ratio11. Our preliminary data (not shown) also indicate that solvent concentration 
affects nanoparticle size above the solubility threshold. Part of this was attributed to 
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clogging of the pore and build-up in the T-junction by aggregates that form at high 
concentrations.  
 
2.3.3.2   Effect of substrate molecular weight on the bioactivity of NPPS. 
Following the analysis of the physicochemical property of the three NPPS preparations (L-
, M- and S-NPPS), we proceeded to examine their immunostimulatory activity to determine 
if a relationship existed between these two parameters. Data presented in Fig. 2.11. showed 
the 24-hr stimulation of NO production by macrophages. Both PS and NPPS displayed 
good dose-dependent effects. As shown in Fig. 2.11, the immunostimulatory potency of 
PS was related to the molecular size; the smallest sub-fraction – ‘S’ – was less potent 
compared to the M and L fraction. This observation was consistent with previous reports 
from Azike et al. and Lemmon et al.6,7. NPPS prepared from these 3 different sub-fractions 
showed higher potency than L-, M- and S-PS, indicating the potency enhancing effect of 
nanosization; however, there were no significant differences among them. This is 
consistent with our previous finding using bulk PS as the substrate which demonstrated 
enhanced potency with nanosization (Fig. 2.7.). We have also found that nanosization had 
the greatest effect on the smallest fraction, with the largest increase in potency. This may 
also suggest that nanosization of a bulk PS sample containing species with a range of 














































































































































Figure 2.11. Immunostimulatory effects of (i) ginseng PS and (ii) NPPS on the production 
of NO by macrophages after 24 hrs. Three molecular weight fractions were used: (a) 30-
50 kDa (S), (b) 50-100 kDa (M) or (c) >100 kDa fractions (L). RAW 264.7 cells were 
treated with 0, 50, 100 or 200 µg/mL of sub-fractionated PS or NPPS for 24 hrs. LPS (1 
µg/mL) was used as the positive control; LPS control was used in each figure for better 
comparison. Experiments were performed in triplicates and the data are presented as mean 
± SEM, n = 3. Data were statistically analysed by one-way ANOVA followed by Dunnett’s 
post-hoc test. * Values P < 0.05 compared to the vehicle (zero) control are statistically 
significant.  
 
This section focused on the influence of the molecular size of PS on its nanosization into 
NPPS. Results of this experiment indicated that PS of different molecular sizes could be 
nanosized by microfluidics into more active immunostimulatory NPPS. These NPPS (S, 
M and L) exhibited similar bioactivity despite some differences in particle size. 
Furthermore, it was demonstrated that microfluidic processing could be applied equally 
well to a heterogeneous mixture of PS (i.e., bulk PS) as compared to more homogeneous 
sub-fractions (i.e., S-, M- and L-PS). This finding may have implications in designing 
future protocols for microfluidics-based nanosization of ginseng PS.   
 
2.4  Conclusions 
We have been successful in preparing NPPS from bulk PS substrate by a continuous 
microfluidics methodology as described by Akhter et al. with modifications11. This 
procedure produced nanoparticles with uniform morphology and narrow size distribution 
of ~10-25 nm. The resulting nanoparticles were unimodal spheres, monodispersed and 
exhibited low agglomeration compared to the bulk material, ginseng PS.  
 
These NPPS showed enhanced immunostimulatory activity as compared to bulk PS when 
tested in cultured RAW 264.7 macrophages. NPPS also demonstrated good penetration 
across the keratinocyte monolayer in vitro, while PS showed little, if any, penetration. 
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These findings provided critical and corroborating evidence supporting our earlier 
observation of the disposition of NPPS, but not PS, in dermal tissues following topical 
application in an animal model. Lastly, a study was conducted to investigate the influence 
of the molecular size of PS substrates on the production of NPPS by the microfluidics-
based nanoprecipitation procedure. This was essential, as the crude PS used in our study is 
known to be heterogeneous, making up of PS of different molecular sizes: ≥ 100 kDa (L), 
50 - 100 kDa (M) and 30 – 50 kDa (S), with sub-fraction ‘S’ showing the lowest 
immunostimulatory activity. Data showed that all three sub-fractions could be prepared 
into nanoparticles with similar yield and comparable enhanced immunostimulatory 
activity.   
 
In conclusion, we have been successful in modifying the microfluidics methodology for 
the preparation of ginseng NPPS from bulk PS. The characterization study has provided 
evidence of well-defined and consistent physicochemical and pharmacological properties; 
this data will support its application in the nutraceutical field. However, its fate in 
biological tissues and organism is largely unknown. Information is needed to address their 
potential toxicity. Future studies should investigate the fate of ginseng NPPS and address 
the potential toxicity associated with nanomaterials. 
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3.1  Introduction 
Panax ginseng (Asian ginseng) is a perennial plant that has been traditionally used as a 
herbal remedy for the treatment of general malaise, gastrointestinal distress and diseases 
of the respiratory system, whereas Panax quinquefolius (North American ginseng) was 
primarily used to relieve cold sores, fevers and gastrointestinal distress1,2. The two major 
phytochemicals in ginseng are ginsenosides and polysaccharides (PS). Ginseng PS are not 
secondary plant metabolites but are part of the cell wall and are released by hydrolysis 
during processing. Polysaccharides are large hydrophilic molecules that have diverse 
composition, conformation and structure. The PS component consists mainly of starch-like 
PS, pectins and hemicellulose, with starch-like PS being the primary carbohydrate 
component3. 
 
Ginseng PS are known as adaptogens, which are substances thought to increase 
physiological resistance to physical and chemical stress. Adaptogenic effects are non-
specific, and; immunomodulation is one of these adaptogenic effects. Ginseng PS have 
been demonstrated in vitro to enhance hydrogen peroxide (H2O2) and nitric oxide (NO) 
production of murine peritoneal macrophages4. PS-treated macrophages were also shown 
to exhibit stimulated lysosomal phosphatase and phagocytic activities4. In addition, 
cytokine production – tumor necrosis factor alpha (TNFα), NO, interleukin (IL)-6 and IL-
1β – was upregulated in RAW 264.7 macrophages (Abelson murine leukemia virus 
transformed macrophages) treated with PS5. Similar upregulation of cytokine production 
was observed in mice treated with orally administered PS6. In a recent preclinical study, a 
ginseng PS extract was reported to increase T and B lymphocyte proliferation and natural 
killer (NK) cell activity in cyclophosphamide-induced immunosuppressed mice7. 
  
North American ginseng roots are marketed as teas, beverages and natural health products 
(NHPs). COLD-FX®️ (CVT-E002), which is one of the best-known NHPs in Canada, is 
manufactured from NA ginseng as a PS extract enriched in polyfuranosyl-pyranosyl-
saccharides. Clinical trials revealed that COLD-FX®️ was effective in preventing acute 
respiratory illness in immunocompetent seniors8. In a more recent clinical trial, a 
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decreasing trend in the incidence of acute respiratory illness in Chronic Lymphocytic 
Leukemia patients taking COLD-FX®️ was reported9. 
 
Ginseng PS act by binding to pathogen recognition receptors (i.e., toll-like receptor (TLR) 
2/4) which trigger subsequent intracellular pathways resulting in an immune response10,11. 
Briefly, dimerization of TLR4 mediates the activation of the nuclear factor-kappa-light-
chain-enhancer of activated B cells (NF-κB) cascade downstream12. Consequently, the 
production of TNFα, IL-6, IL-1β and NO are upregulated, to name a few13,14. In addition 
to the NF-κB cascade, ERK-1/2, PI3K and p38 pathways have been implicated in the 
immunomodulatory effects of ginseng PS15. Following TLR activation, cell-surface TLRs 
are internalized, which reduces the responsiveness of immune cells to TLR agonists16,17. 
The TLRs are endocytosed as a complex with the TLR ligand, which may be mediated by 
cluster of differentiation 14 (CD14)17,18. This is commonly known as TLR desensitization 
or TLR tolerance in macrophages. Animal lectins that can recognize and bind 
carbohydrates are another potential receptor for ginseng PS19. These potential mechanisms 
of activation of PS may differ following microfluidic processing to synthesize 
nanoparticles of ginseng PS (NPPS). 
 
Nanoparticles are particles with at least one-dimension that ranges from 1 – 1000 nm. They 
are surrounded by a surface/interfacial layer, which is the “region intermediate between 
two bulk phases in contact”20. This region may or may not contain other inorganic materials 
or ions, depending on the methodology used to prepare them. Nanotechnology is often 
applied to compounds that are poorly soluble and large in size to produce nanoparticles 
while controlling these properties21,22. Nanoparticles typically exhibit size-related 
properties different from their substrate compound23,24. They have been shown to have 
higher permeability than the drug or substrate that was used to prepare them25. The 
enhanced permeability is generally attributed to the reduction in particle size and alteration 
of surface chemistry (ex. polarity, solubility, etc.)22,24,26. 
 
NPPS possess different potencies than its substrate, in addition to different 
physicochemical properties. Bulk PS are present in solution as large micron-sized particles 
76 
 
and agglomerates whereas NPPS have a uniform and spherical nanomorphology. These 
NPPS have exhibited greater immunostimulatory activity (NO, TNFα, IL-6) in vitro 
relative to regular ginseng PS (i.e., bulk PS)6. Ginseng NPPS have been shown to correlate 
with greater NO and cytokine (TNF-α) levels in murine blood samples collected by cardiac 
puncture following oral gavage6. In addition, higher levels of IL-1β, TNF-α and NO in 
blood serum and skin samples have also been reported in hairless mice topically treated 
with ginseng NPPS6. Previous research indicated that ginseng NPPS accumulated within 
the macrophages with no apparent retention at the cell membrane and showed earlier 
intracellular uptake6. On the other hand, ginseng PS was retained at the cellular membrane6. 
Although NPPS appeared to exhibit higher immunostimulatory activity and showed 
enhanced cellular uptake; the underlying mechanism is poorly understood. Accordingly, 
the present study has been conducted to test the hypothesis that NPPS do not share the 
same cellular mechanism in mediating its immunostimulatory action as compared to PS.  
In order to do this, we examined the role of TLRs by i) defining the time-course of 
macrophage activation; ii) assessing the influence of TLR desensitization by LPS; and iii) 
suppression of activation by selective TLR antagonist. Our data showed that in contrary to 
our hypothesis, NPPS behaved like PS under these experimental conditions.  
 
3.2   Experimental Procedure 
3.2.1 Materials 
Ginseng PS were extracted and isolated from aqueous extract of Panax quinquefolius 
which was provided by the Ontario Ginseng Innovation and Research Consortium. 
Deproteinated PS (i.e., bulk PS) was used to synthesize ginseng NPPS by nanoprecipitation 
using microfluidics (Fig. 2.1)27. Subsequently, the resulting nanomaterials were 
characterized for its physicochemical properties (Ch. 2.2.) prior to performing 
pharmacological studies on ginseng NPPS.  
 
Abelson murine leukemia virus transformed macrophages (RAW 264.7) (ATCC TIB 67) 
provided by Dr. Jeff Dixon (Department of Physiology and Pharmacology, University of 
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Western Ontario, Canada) were used for pharmacological studies. Dulbecco’s Modified 
Eagle’s Medium (DMEM) and Fetal Bovine Serum (FBS) (US origin) were purchased 
from Gibco laboratories (USA). Lipopolysaccharides from Escherichia coli (O111:B4), 
Sparstolonin B (SsnB) and Griess’ reagent (modified) were purchased from Sigma-Aldrich 
(Canada). 
3.2.2 Macrophage cell culture and marker of activation 
RAW 264.7 were cultured in DMEM supplemented with 10% Fetal Bovine Serum (FBS) 
and 1% penicillin/streptomycin. Cell cultures were maintained at 37 ℃ in a humidified 
incubator with 10% CO2. The concentration of CO2 was used in accordance with the 
concentration of sodium bicarbonate (3.7 g/L) within the media to maintain a pH of ~ 7.4. 
RAW 264.7 cells were passaged every 3-4 days at approximately 80% confluency. Cell 
culture media were changed one day prior to passaging. Cell cultures were tested for 
mycoplasma contamination and were negative for contamination. For experiments, RAW 
264.7 cells were seeded in 96-well tissue culture plates at a density of 1.5 x 105 cells per 
well and incubated at 37 ℃ and 10% CO2.   
 
The marker of macrophage activation was the induction of iNOS, which was assessed by 
measuring NO production via colorimetric detection of the presence of nitrite ions in the 
media. Nitrite is a final product of the NO oxidation pathway. Nitrite was quantified using 
a modified Griess’ reagent containing 0.5% sulfanilic acid, 0.002% N-1-naphthyl-
ethylenediamine dihydrochloride and 14% glacial acetic acid (Sigma-Aldrich, USA). 
Briefly, 50 µL of Griess’ reagent was added to 50 µL of culture supernatant and incubated 
away from light at room temperature for 15 mins. Absorbance at 540 nm wavelength was 
measured using uQuant microplate reader (Biotek Inc.). Nitrite concentrations in samples 
were estimated from the standard curve prepared by dilutions of sodium nitrite. 
3.2.3 Time-course of immunostimulation  
To determine the onset of action, RAW 264.7 cells were treated with 200 µg/mL of PS or 
NPPS for 6, 9, 12, 15, 18, 21 or 24 hrs. Macrophage response to PS or NPPS was 
determined by measuring the NO level in the culture supernatant.  
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3.2.4 Effect of TLR desensitization by LPS pre-treatment 
To determine whether NPPS act via binding to TLRs and followed by internalization (i.e., 
translocation), a model of LPS-induced desensitization of macrophage responsiveness via 
treatment-induced internalization of TLRs was used. This model was set-up by pre-treating 
cultured RAW 264.7 cells with 1 µg/mL of LPS or vehicle control (media) for 24 hrs to 
induce TLRs internalization. Following pre-treatment, LPS-challenged macrophages were 
washed three times with PBS to remove the remaining LPS. Cells were subsequently 
treated with 50 and 200 µg/mL of ginseng PS or NPPS. LPS (1 µg/mL) was used as the 
positive control. At 24 hrs, cell culture supernatant was removed. The end-point was 24 
hrs NO production by macrophages.  
3.2.5 Effect of pre-treatment with a selective inhibitor of TLR 2/4 (Sparstolonin B) 
To determine the role of cell surface toll-like receptors in the mediation of NPPS activity, 
SsnB, a selective TLR2/4 antagonist, was used to inhibit downstream TLR signalling in 
cultured macrophages28. For this, cultured RAW 264.7 cells were treated with or without 
SsnB (10 µg/mL and 100 µg/mL). Cells were treated concurrently with ginseng PS or 
NPPS (200 µg/mL).  At 24 hrs, cell culture supernatant was removed for determination of 
24 hrs NO accumulation.   
3.2.6 Statistical analysis  
Data are present as mean ± standard error of the mean (SEM). The two-way analysis of 
variance (ANOVA) followed by Bonferroni’s post hoc test was used for the comparison of 
means between treatment groups. Statistical analysis was performed using GraphPad Prism 
6 software (San Diego, CA). Values P<0.05 compared between treatment groups were 




3.3   Results and Discussion 
3.3.1   Time-course of immunostimulatory effect of PS and NPPS in macrophages in 
vitro 
To investigate if NPPS and PS have a different mechanism of action, the onset of 
immunostimulation in vitro was studied. This was studied by treating cultured 
macrophages with bulk PS or NPPS for 24 hrs and examined the response in 3-hr intervals. 
Bulk PS treatment induced significant NO production over control values beginning at ~ 
15 hrs (Fig. 3.1). Nitric oxide production from PS stimulation reached plateau at ~ 18 hrs. 
On the other hand, the earliest significant increase in NO production with NPPS was 
observed at ~ 12 hrs; and maximum stimulation was noted at ~ 15 hr. In summary, 
compared to bulk PS treatment, NPPS treatment elicited a greater maximal response in 













Figure 3.1. Immunostimulatory effects of ginseng PS and NPPS on macrophage nitrite 
production. Stimulation of RAW 264.7 macrophages by ginseng PS or NPPS. RAW 264.7 
cells were treated with 200 µg/mL of PS and NPPS for 6-24 hrs. Three independent 
experiments were performed in triplicates and the data are presented as mean ± SEM. 
Datasets were statistically analysed by two-way ANOVA followed by Bonferroni’s post 











The observed time-course of action of NO production is consistent with the reported 
activation of the TLR-dependent NF-κB signalling pathway induced by pathogen 
associated molecular patterns (PAMPs). Jacobs et al. also reported a similar finding 
pertaining to LPS induced iNOS protein response in RAW 264.7 cells29. In this study, 
detectable levels of NO with NPPS and PS treatment groups were observed at ~ 9 hrs. 
Consistent with our results, NO production rate was reported by Jacobs et al. to reach 
steady-state levels at ~ 9 hrs before reaching maximum plateau29.  For NPPS-treated 
macrophages, NO levels increased linearly until a maximum plateau at approximately 15 
hrs following treatment, similar to the time taken to reach the plateau phase observed by 
He et al.30. In addition, we have previously determined that ginseng extracts can elicit 
optimal stimulation at approximately 24 hrs. The significance of the earlier onset of action 
associated with NPPS treatment (Fig. 3.1.) is not clear; however, this appears to support 
the earlier cellular uptake of NPPS compared to PS as determined by bioimaging using 
RAW 246.7 macrophages6. The observed difference in time-course of action between 
NPPS and PS suggests that NPPS may not mediate its cellular activation by the activation 
of TLR signalling pathway that has been well established for PS. Some nanomaterials have 
been shown to penetrate the cell which allows for the activation of intracellular 
mechanisms31–33.  
3.3.2 Immunostimulatory effects of NPPS in LPS-desensitized macrophages in vitro 
To determine the involvement of the TLR signalling pathway in mediating the action of 
NPPS, we desensitized macrophages with prior LPS treatment for 24 hrs to induce TLR 
internalization. These cells were then challenged with 0, 50 or 200 µg/mL of PS or NPPS 
treatment to assess their responsiveness. LPS were used as the positive control to establish 
standard cellular responsiveness. NO production was measured as a basis for macrophage 
responsiveness to LPS, PS or NPPS. As shown in Fig. 3.2, pre-treating macrophages with 
LPS reduced the macrophage response to subsequent LPS stimulation by ~ 48%.  This 
finding is consistent with our earlier report5. The observed reduction in responsiveness is 
believed to be a result of the reduced presence of cell-surface TLRs and the attenuation of 
responsiveness to TLR agonists17,34. A study by Rajaiah et al. showed that the induction of 
tolerance by exposure of macrophages to LPS induced TLR4 endocytosis18. The apparent 
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LPS-induced loss of responsiveness was not due to artifacts resulting from additional 24-
hr incubation since pretreatment with the vehicle did not alter the macrophage 
responsiveness. Additionally, the response to PS and NPPS in macrophages pretreated with 
the vehicle for 24 hr showed good dose-dependency and was comparable to what we 
reported in Chapter 2 for regular (non-treated) macrophages (Fig. 2.4). Data presented in 
Fig. 3.2 also showed that LPS-pretreatment reduced the responsiveness to both levels of 
PS and NPPS challenges by 33 to 50%. This finding suggested that NPPS like PS is an 
agonist of TLR in view of their sensitivity to LPS-induced desensitization. However, it 
should be noted that because the LPS-induced desensitization on NPPS and PS was less 
















Figure 3.2. Immunostimulatory effects of ginseng PS and NPPS on macrophage NO 
production. RAW 264.7 cells were pretreated with vehicle or LPS (1 µM) for 24 hrs prior 
to treatment with 200 µg/mL of NPPS or PS for 24 hrs. LPS was used as a positive control 
to evaluate cellular responsiveness. Experiments were performed in triplicates and the data 
are presented as mean ± SEM, n =3. Data were statistically analysed by two-way ANOVA 






































followed by Bonferroni’s post hoc test. *Values P < 0.05 compared between pre-treatments 
are statistically significant. 
3.3.3 TLR 2/4 antagonist suppressed NPPS activity 
To further ascertain whether TLR2/4 are involved in the mediation of NPPS activity, a 
selective antagonist (SsnB) was used to inhibit the recruitment of myeloid differentiation 
primary response 88 (MyD88) to TLR2/4 in macrophages, which is a critical step in the 
activation process. As expected with PS, the presence of SsnB significantly reduced PS-
mediated NO production by macrophages (Fig. 3.3). The degree of inhibition was related 
to concentration of the antagonist: 10 µg/mL and 100 µg/mL SsnB, induced a ~ 60% and 
~ 98% reduction, respectively. A similar concentration-dependent SsnB induced reduction 
of NPPS-mediated NO production by macrophages was also observed.  
 
Sparstolonin B is a novel compound isolated from Sparganium stoloniferum that has been 
demonstrated to inhibit signalling pathways (i.e., MAPK and NF-κB) downstream of 
TLR2/4 activation. Considerable evidence suggests the presence of SsnB intracellularly 
inhibits the ligand-induced association of MyD88 to TIR-domain-containing adaptor 
protein (TIRAP) and TLR2/4 complex28. Therefore, a reduction in the macrophage 
response to TLR2/4 agonists is expected as a result of the reduced MyD88 association. 
Together with the purported SsnB antagonistic activity, these lines of evidence suggest that 
ginseng NPPS, like PS, act on TLR2/4 signalling. Furthermore, the marked suppression of 
NPPS action in the presence of a selective TLR 2/4 antagonist observed in this experiment 
strongly implicates the involvement of the TLR pathway in mediating the 
immunostimulatory action of NPPS.  In addition, in light of the known mechanism of 
action of the antagonist used, the site of action of NPPS and bulk PS could be narrowed 























Figure 3.3. Immunostimulatory effects of ginseng PS and NPPS on macrophage NO 
production over a 24-hr period. RAW 264.7 cells were treated in the presence of 10 or 100 
µg/mL SsnB and, with 200 µg/mL of PS or NPPS for 24 hrs. Treatment with PS or NPPS 
in the absence of SsnB were the negative controls. Experiments were performed in 
triplicates and the data are present as mean ± SEM, n =3. Data were statistically analysed 
by two-way ANOVA followed by Bonferroni’s post-hoc test. *Values P < 0.05 compared 
with the negative control within the treatment group are statistically significant.  
 
Ginseng and other plant PS have been reported to activate TLR2 or TLR4 signalling. For 
example, Agaricus brasiliensis beta-glucans has recently been shown to enhance 
phagocytic activity of monocytes via TLR2/4 signalling35. In another study, ginseng PS 
immunostimulation was impaired in TLR4 deficient mice (C2H/HeJ)36. TLR2 and TLR4 
have also been implicated in the response of mammary glands treated with ginseng 
extracts37. Shin et al. reported that CD14 was upregulated in macrophages treated with a 






















10 μg/mL SsnB 




macrophages10. A contemporary study showed that smaller chains of ginseng PS activate 
TLR2 as opposed to TLR411. Therefore, ginseng PS may be directly binding to CD14 or 
TLR2/4 to elicit a response. Our data suggest that both NPPS and PS may mediate 
macrophage response via TLR signalling; however, it is not certain whether the molecular 
mechanism of PS could be extended to NPPS. This question should be addressed by taking 
into consideration that microfluidics processing was demonstrated to not functionally alter 
ginseng PS, but rather alter surface chemistry.  
 
The activation of TLR signalling by NPPS may be through binding to CD14 or directly to 
TLR2/4. The binding to CD14 has been studied with reference to LPS38,39. This usually 
involves the interaction of LPS aggregates to CD14, which catalyzes its monomerization 
prior to presentation to TLR439,40. Based on their data, Kitchens et al. proposed that 
monomeric LPS-CD14 complexes are necessary to elicit a response38. Similarly, ginseng 
PS exists in aqueous solution as aggregates. It is not certain how NPPS, which has a smaller 
particle size than PS, would behave under this condition. However, it is possible that 
ginseng PS and NPPS also require monomerization by CD14 and presentation to TLR4. 
Ginseng NPPS may also be more potent than PS due to the smaller apparent size of its 
agglomerates. This is supported by the report that aggregates of LPS are less potent when 
their aggregates sizes were increased41. With this consideration, we propose that 
nanosization enhances binding affinity through the reduction in particle size. 
 
The observation that NPPS stimulated macrophages earlier and to a greater extent than 
bulk PS suggested the possibility of a different mechanism of activation between NPPS 
and bulk PS. Alternatively, NPPS may be acting via similar mechanism(s) as bulk PS but 
act faster and more efficiently to achieve high maximum response. Higher receptor affinity 
or involvement of accessory proteins are possible explanations for this speculation. 
Partially reduced responsiveness was observed following LPS-desensitization in both 
NPPS and PS conditions. This suggested that they may share the same pathway of 
activation; although, they may still act differently at certain levels (e.g., CD14). The 
observed reduction could also be the result of non-specific effects of LPS. The hypothesis 
that NPPS act differently than bulk PS was refuted by the activation of TLR signalling by 
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the nanoparticles, but the possibility of a different mechanism should not be entirely 
discarded. It is possible that additional mechanism(s) may exist in conjunction with TLR 
activation, or other mechanism(s) of activation by PS such as animal lectins have been lost 
following nanonization. Further studies are needed to determine other potential receptors 
of NPPS. Despite this, the results of this experiment have enabled us to begin to elucidate 
the basis behind the enhancement of PS’ stimulatory effect following nanonization. 
 
Alternative pathways for NPPS activation of macrophages could be examined in future 
studies. Other potential receptors for ginseng PS are complement receptor-3 (CR3), 
scavenger receptor (SR), dectin-1 and mannose receptors, which have been demonstrated 
to bind to carbohydrates and are implicated in the activation of the NF-kB pathway in 
macrophages19,42. Dectin-1 and mannose receptors are animal lectins (carbohydrate-
binding proteins) that have high specificity for sugar moieties19. Dectin-2, galectins and 
immunoglobulin-like lectins are other animal lectins that have been implicated in the 
immunostimulatory activity of botanical polysaccharides19.  
 
3.4   Conclusions 
The objective of this chapter was to investigate the mechanism of immunostimulation 
exerted by NPPS that was prepared by microfluidic processing from ginseng PS. The 
strategy was to define the time-course of action in cultured macrophages and to determine 
whether NPPS shared a different mechanism as PS and LPS. Our data showed that NPPS 
has a faster onset of action and a higher maximum response than PS, which corroborated 
with the bioimaging data from our previous study using macrophages. Using an LPS-
induced desensitization model involving increased TLR internalization and downstream 
negative regulation of TLR signalling, we showed that TLR-dependent pathway was 
involved – at least in part – in the mediation of action of NPPS and PS. Furthermore, the 
successful suppression of NPPS and PS-induced immune response with the selective 
TLR2/4 antagonist, SsnB, has provided evidence to identify a site in the TLR4 signalling 
upstream of ligand-induced MyD88 association. It is likely that NPPS act similar to 
ginseng PS in activating TLR-mediated NF-κB signalling; however, it remains to be 
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determined whether other mechanism(s) may be involved and the basis underlying the 
more rapid onset and higher potency of NPPS.   
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4.1  Summary and conclusions 
4.1.1 General objectives 
In this project, two primary objectives have been addressed pertaining to the conversion of 
ginseng PS to their nanoparticle form by microfluidics: (1) modification of the existing 
microfluidics methodology for NPPS synthesis and characterization of their 
physicochemical and pharmacological properties; and (2) investigation of mechanism(s) 
underlying the immunostimulatory activity of nanoparticles to provide insight into the 
cellular action and target(s) of NPPS.  
 
4.1.2 Modification of microfluidics methodology 
Modification of the microfluidics procedure developed by Akhter et al. has provided 
information regarding its limitations and undefined variables (i.e., substrate concentration). 
The main limitations associated with the previously reported methodology are low total 
yield and susceptibility to poor sample recovery. Based on the physicochemical 
characterization data, we could conclude that the modified microfluidic methodology was 
able to produce NPPS from bulk PS with a reasonable yield of approximately 95 %, and a 
size distribution averaged around 19 nm. The NPPS exhibited monodispersed and spherical 
nanomorphology, which is characteristic of previously synthesized NPPS.  
 
4.1.3 Biological and physicochemical characterization of NPPS 
Biological characterization of the resulting NPPS revealed that microfluidic processing of 
bulk PS enhanced its immunostimulatory activity in vitro. Data from this experiment 
assisted in the development of a novel macrophage-based bioassay for PS and NPPS 
quantitation in order to address the lack of plant PS quantitation technology. Furthermore, 
coupling a keratinocyte monolayer model with the macrophage-based bioassay has 
provided a new in vitro system to assess bioavailability. By utilizing this system, we were 
able to study the transport of PS and NPPS across a cellular membrane barrier. Moreover, 





Using this novel technology, we have demonstrated that NPPS showed significant 
penetration across an established keratinocyte monolayer that acts as an effective barrier 
for bulk PS. These findings provided insight into the potential relationship between reduced 
particle size and enhanced permeability of ginseng NPPS.  
 
While investigating the relationship between substrate molecular weight and the 
characteristics of NPPS, we were able to conclude that molecular size of the PS substrate 
influenced the physicochemical property and immunostimulatory potency of NPPS. 
However, findings revealed that nanosizing enhanced the potency of lower molecular 
weight bulk PS, which exhibited lower immunostimulatory potency relative to the higher 
molecular weight PS.  
 
4.1.4 Mechanism of macrophage activation by NPPS 
The mechanistic study of ginseng NPPS reported in Ch. 3 demonstrated reduced 
responsiveness of desensitized-macrophages to NPPS and impaired NPPS-induced 
response in macrophages treated together with an antagonist. Results from this study 
demonstrated the importance of TLR2/4 signaling in NPPS activation of macrophages and 
supports the conclusion that NPPS behave like ginseng PS. Taken together with the 
physicochemical prosperities of NPPS, these findings have allowed us to conclude that 
nanonization of bulk PS does not alter its ability to activate TLRs. 
 
4.2  Challenges and solutions 
The low sensitivity and specificity of the biological assay for PS and NPPS estimation of 
concentration is one of the major challenges associated with our study. To address this 
issue, we have proposed to develop a more sensitive and specific measurement of cellular 
marker for immunomodulation using new biotechnology such as cytokine gene expression. 
This would be advantageous for the detection of immunostimulatory responses to low 
concentrations of PS and NPPS, thereby allowing us to estimate sample concentration with 





Another major challenge is the lack of tools for PS and NPPS bioimaging. To address this, 
we propose the development of quantum-dot labelling-technology for ginseng PS that 
would allow for quantification, tracking and detection under in vivo and in vitro conditions. 
In addition, it would be beneficial to develop an innovative labelling methodology that is 
based on quantum dot technology. 
 
4.3  Future studies  
Looking at the project holistically, we suggest studying the structure-activity relationship 
between NPPS physicochemical characteristics and ginseng PS immunomodulatory effect 
to expand our understanding in this field. Elucidation of this relationship would offer 
helpful insight in determining why NPPS are more potent than bulk PS. In addition, it is 
important to investigate why NPPS exhibited higher immunostimulatory potency through 
more in-depth mechanistic studies. 
 
We did not have the opportunity to investigate potential toxicity of NPPS in vivo, thus, 
further investigation on the disposition, pharmacology and safety of NPPS in a biological 
system is necessary. Furthermore, NPPS sub-cellular localization, translocation and 
transcription site in macrophages have not been defined. Detailed bioimaging would be 
very useful to define how NPPS exert their effect as well as their fate in macrophages. 
These follow-up studies would enable the development of innovative and safe 
nutraceuticals. 
 
The interaction and fate of NPPS with keratinocytes have not been previously addressed. 
Keratinocytes were used as a model in this current study to assist in the physicochemical 
characterization of NPPS. Therefore, as a follow-up study, examining the response of 
keratinocytes following NPPS treatment would assist in developing a more specific 
biological assay and determining toxicity. In addition, using bioimaging would be helpful 
in addressing its transport and fate in keratinocytes. Alternatively, using fluorescent 
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markers for various proteins associated with endosomes would expand our understanding 
of the transport of these nanomaterials. 
 
Other potential receptors of ginseng PS (e.g., animal lectins) have been identified in the 
literature; however, their implications have not been fully understood. Therefore, it would 
be helpful to determine alternative mechanisms of activation by ginseng PS and its 
nanoparticle counterpart. These findings would support or oppose the claim that 

























Figure A.1. Standard curve for biological assay of (a) ginseng PS and (b) NPPS. Twenty-
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